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1 INTRODUCTION 
Digitalization has already affected many industries, and the new digital technologies are 
expected to change the used business models. People, matters, and industries are more 
connected to each other and information can be copied without errors infinite number of 
times which offer companies new types of value creation and capture, leaner processes, 
and improved customer experience. However, such as lack of funding, existing IT 
systems’ limitations and regulatory concerns create barriers for many industries in regards 
of digitalization (Chircu, Sultanow & Sözer, 2017). 
In many developed countries, the healthcare industry is continuously developing and 
accommodating to new technologies and trends (Shakshuki & Reid, 2015). New 
technological and medicinal advances offer innovative opportunities to create cooperative 
networks between public and private practices (e.g. in health care domain) and most 
importantly, opportunity to offer improved quality services for the patients (Länsisalmi, 
Kivimäki, Aalto, & Ruoranen, 2006). These innovative medicines and technologies can 
benefit everyone globally (Garrisson & Towse, 2017). Furthermore, it is important for 
healthcare organizations and systems to stay current with new technologies because, as 
all the information, also medical information is rapidly increasing (Länsisalmi et al., 
2006). 
The pharmaceutical industry has also recognized the potential of digitalization and the 
opportunities it brings, but the companies are still figuring out the required capabilities 
that are needed to develop and further capitalize these new opportunities (Chircu et al., 
2017). One opportunity that digitalization in the pharmaceutical industry can bring is the 
digital health. Digital health means the use of internet, digital and mobile technologies in 
improving health and/or treating some specific medical condition (Afra et al., 2018). 
Kvedar et al. (2016, p. 240) describe the benefits of digital medicine as: “Patients can 
now be reached before, during and after chronic disease development, interventions can 
be delivered continuously, and deployment can occur either inside or outside the 
healthcare system. This is the promise of digital medicine” (Kvedar, Fogel, Elenko, & 
Zohar, 2016). A closely related term, digital therapeutics, refers to a treatment where 
digital systems are used to treat medical conditions. Digital health data that is gathered 
through the digital therapeutic tools, can be recognized as a considerable opportunity for 
J. Vilponen: Digital Therapeutics Solution and Business Model Creation 
2 
 
patients, pharmaceutical companies, and clinics (Sverdlov et al., 2018). Digital 
technologies and therapeutics have shown evidence in pain relief using Virtual Reality 
(hereinafter referred to VR) technology as well as drug-device combination therapies. 
The focus of digital therapeutics is usually on behavioural therapies and selfcare, whereas 
adding the pharmaceutical drugs could offer considerable benefits for the patient (Afra et 
al., 2018). 
The effectiveness of digital therapeutics can especially be found in the areas of chronic 
diseases as well as diseases with behavioural and physical aspects because these diseases 
are able to receive value from real-time behaviour and health status monitoring. 
Furthermore, these diseases are usually not managed appropriately by the healthcare 
systems and expose them to vast expenses. Hence, compared to more conventional 
therapies, the digital solutions can be accessed more easily and with substantially lower 
costs (De Luca, 2019). Individuals suffering from chronic illnesses can have challenges 
with their self-esteem and mental health. For being able to prevent some of these 
challenges, digital platforms can be used as an enhancement tool to motivate and engage 
the patient and at the same time increase their self-esteem. Furthermore, this kind of 
intervention can increase the results of the physical treatment (Bedrov & Bulaj, 2018). 
One of the most significant challenges that the pharmaceutical companies is facing with 
regard to digital therapeutics are the complexity and slowness of regulatory processes. 
Because of the novelty of digital therapeutics, regulatory requirements and authorization 
are not yet developed (Afra et al., 2018). Moreover, companies are struggling to find 
feasible reimbursement models for digital therapeutics. Existing reimbursement models 
do not necessarily work, and new and yet innovative business models need to be created, 
developed, and studied (Kvedar et al., 2016). Business models are not yet established 
either because of the complexity or diversity of digital medicine. Companies are unsure 
whether these technologies should be the core product or just as an enhancement tool. 
The increasing competition in the digital health space makes it difficult for companies to 
choose a development path and commercialization strategy to distinguish their product. 
Validation and regulation still remain as key determinants (Hird, Ghosh, & Kitano, 2016). 
Furthermore, not only the new health technologies and development of them might 
increase the quality requirements (Lameire, Joffe, & Wiedemann, 1999), but also, the 
technology itself might create some difficulties for the provider and delivery systems 
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because they lack experience and do not receive any guidance about the use of these 
technologies. Because of this, the providers do not have any estimations about the 
effectiveness of the technology. Moreover, the maintenance and installation of these 
technologies create additional work for the IT staff in the organization. Moreover, cost 
calculations and return on investments do not exist because of the lack of these 
assumptions and financial models (Coye, Haselkorn, & DeMello, 2009). 
1.1 Motivation and Research Objectives 
As presented in the introduction, the need for this research is in this growing business 
area and its various potentials that are not much researched. Thus, this research will 
contribute to uncertainty of existing regulations and needs for business models in the 
digital therapeutics field. Furthermore, the need for this research has arisen from a client 
company that is developing a digital therapeutics solution for chronic low back pain. The 
main objective of this thesis is to find a feasible business model for the digital therapeutics 
solution being developed by the client company. The business model needs to convince 
the various stakeholder groups within and outside the client company. Because of the 
novelty of digital therapeutics solutions, the already existing business models in other 
digital therapeutics companies are able to provide vital background information regarding 
the development of the business model.  
In order to support the decisions made for the business model, analysing and scanning the 
business environment is essential. This thesis covers companies internationally and does 
not only focus on digital therapeutics companies in the EU. The USA is the leading  
national market for pharmaceutical products (Dubois, de Mouzon, Scott-Morton, & 
Seabright, 2015) and thus, it is a compelling market for many global pharmaceutical 
companies, as it is for the client company as well as the case companies presented in this 
thesis.  
The objectives of the research have motivated the development of research questions that 
will support the overall perspectives of this thesis. The research questions are: 
- RQ1: What kind of business environment exists for the client company?  
- RQ2: From the business model perspective, what type of characteristics arise in 
existing digital therapeutics companies?   
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- RQ3: Which of these characteristics are feasible in the client company’s business 
model?  
- RQ4: Which characteristics are perceived important by different stakeholder groups 
within and outside the client company? 
1.2 Structure of the Thesis 
The thesis commences with an introduction to the thesis topic and defines a research gap 
that motivates the research objectives and questions. The second chapter consists of a 
literature review that aims in providing a thorough understanding of the business 
environment. This is followed by an introduction of theoretical background that presents 
frames for the conducted research and for further analysis of the results. The fourth 
chapter explains the research methodology by describing the research and data collection 
methods as well as motivates the chosen research methods for this thesis. For the purpose 
of multiple-case study and in-depth interviews, the fifth chapter provides background 
information about the client company and five case companies. In the following chapter, 
the results from multiple-case study and in-depth interviews are introduced and supported 
by theoretical background. The seventh chapter contributes in analysing the results 
through comparing the case companies and combining the stakeholder perceptions. Based 
on the results, a suggestion for a business model is described. In conclusion, the key 
findings from the research based on literature are presented and discussed. Finally, the 
practical and theoretical implications are considered followed by limitations and future 
research suggestions.  
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2 LITERATURE REVIEW 
This literature review aims at describing the business environment that exists for the 
digital therapeutics solution. The understanding of the environment supports the business 
model design and contributes in more informed decision-making (Osterwalder & Pigneur, 
2010). The literature review describes the demographic changes resulting in a 
requirement for transforming the delivery of health care. Furthermore, the different health 
care and reimbursement systems are introduced and the arising needs for health care value 
delivery are discussed. Then, the digitalization’s possibilities for pharmaceutical industry 
and digital therapeutics are introduced. Lastly, the various means of pricing digital 
content are considered.  
2.1 Delivering Health Care 
Demographics of the population are changing (Länsisalmi et al., 2006) while in many 
countries, the aging population increases the demand of health care by typically being 
more dependent on the services offered by the state (Shakshuki & Reid, 2015; Lameire 
et al., 1999). Moreover, people are dependent on the economy at the beginning as well as 
end of life because their consumption exceeds the income generated through labour input 
(Hammer, Prskawetz, & Freund, 2015; Wendt, Kohl, Mischke, & Pfeifer, 2010). 
However, the aging population does not only mean that the number of patients and acute 
trauma levels are increasing but also that the workforce, especially nurses, are retiring 
which results in a lack of skilled staff (Länsisalmi et al., 2006). Current health care 
systems will be pressurized because the number of elderly people is increasing, and they 
need to be covered by government funds. However, the population in working age is 
shrinking due to lower fertility and aging population (Hammer et al., 2015).  
Due to this change in age structure, economies need to consider the economic life cycle 
and economic age pattern of economic activities such as consumption, the generation of 
labour income, and saving. Consequently, societies need to reallocate their resources as 
well as reallocate the age system (Hammer et al., 2015). Physical inactivity, unhealthy 
diets, and other changes in lifestyles in addition to aging population have increased the 
amount of chronic conditions. Additionally, even more patients suffer from multiple 
morbidities (OECD, 2016). Thus, personalized healthcare will be important due to these 
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complex diseases and differences in responding to treatments by each patient. Innovation 
and improvement regarding medicine, treatment, and health care are essential in order to 
answer the patients’ needs (Garrison & Towse, 2017). 
In the European countries, social values that are embedded in societies guide the public 
attitudes with regard to the state’s responsibility in health care. In most European 
countries, thus, health care funding comes from the public. Satisfaction for health care is 
more a personal experience and hence the institutional differences matter for citizens. At 
the individual level the more satisfaction towards a health care system is felt when the 
patient feels that the doctor actually gave time for the patient (Wendt et al., 2010). Hence, 
the need for quality in health care is rising among patients and citizens (Bodolica, 
Spraggon, & Tofan, 2016; Lameire et al., 1999). When patients and third-party payers 
become more aware of value of health care, value-based pricing and reimbursement 
become more important (Garrisson & Towse, 2017). In addition, governments are 
pressured to increase the quality of healthcare while reducing costs (Länsisalmi et al., 
2006). 
2.1.1 Health Care Systems  
Health care systems reflect on the citizens’ social and cultural expectations because they 
are affected by the values and norms in society. The unique history, traditions and 
political systems have modified different health care systems to each country. In some 
societies, health care is viewed as a social or collective good accessible for every 
individual regardless of his status, need or age, whereas some see it as a commodity 
bought and sold on the open market. Despite this difference, each health care system aims 
for a perfect balance of access of healthcare, quality of care, and cost efficiency (Lameire 
et al., 1999). 
Health care delivery and finance can be depicted as a triangle. In Figure 1, the exchange 
and transfer of resources between parties is illustrated. The providers transfer health care 
resources to patients, and patients or third parties then transfer financial resources to 
providers. In the simplest form, the consumer (the first party) pays directly to the provider 
(the second party) in exchange for the service or good (Mossialos & Dixon, 2002). 
However, the health care systems have been developed to share the consumer’s financial 
risk of falling ill and uncertainty of actions taken in such an event. Thus, a third party (a 
J. Vilponen: Digital Therapeutics Solution and Business Model Creation 
7 
 
public or a private body) collects direct or indirect payments from the population it 
protects in order to reimburse the patient or the provider. The third party’s responsibility 
is to determine a health benefit package or health plan that covers the correct and relevant 
medicines, tests, and procedures (Garrisson & Towse, 2017; Mossialos & Dixon, 2002). 
There are three functional components in health care systems that can be either integrated 
or separated in several combinations: revenue collection, fund pooling, and purchasing 
and provision of health care. When these functions are separated, the resources are 
allocated between entities that have focused either in collecting and pooling of funds or 
purchasing and providing the services. The revenue collection is the process of collecting 
funds for the health care system (see Figure 2) (Mossialos & Dixon, 2002).  
Mainly the funding comes from individuals or corporate entities in the means of taxes, 
social health insurance contributions, private health insurance premiums, medical savings 
account or out-of-the-pocket payments. Taxes and social health insurance funds are 
usually compulsory payments collected through e.g. income, payroll and commodities by 
the government or employer and reserved for health and social service expenses. Private 
health insurance premium’s price is determined by risk ratings based on different 
assessment and criteria of requiring health care. Private for-profit or not-for-profit 
insurance companies and funds collect the payments from individuals, employers, or the 
combination of these two. An individual can reserve funds into a medical savings account 
which usually is combined with a high-deductible catastrophic insurance. Out-of-the-
pocket payments are collected by the service provider as a flat rate payment for each 
service or co-insurance payment as a percentage of the total cost of the service. In some 
Figure 1 Healthcare Triangle (Mossialos & Dixon, 2002) 
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cases, the insurer covers the remaining costs if the patient has reached the so-called ceiling 
amount of payments (Mossialos & Dixon, 2002). 
In the fund pooling function, the financial risk is pooled across the population or a defined 
subgroup. Taxes are collected and used by the same agent which makes the allocation 
from collection agent to pooling agent internalized. However, a mechanism is required to 
distribute the resources from the collection agent to the pool in case different agents carry 
out these functions. Furthermore, in case of multiple pools the risk profile and needs of 
population covered by each pool determines the allocation of resources. This enables 
equal access of health care to each individual. In the private health insurance model, the 
funds are pooled between the subscribers of the same insurance provider, whereas in the 
medical savings account the pooling is not possible. Hence, these individuals usually 
acquire an additional catastrophic insurance. Out-of-the-pocket payments do not either 
have the pooling function, but they serve as a revenue for the healthcare provider to 
maintain the service and cover costs. In some cases, however, the user charges might be 
Figure 2 The Process of Funding Healthcare (Mossialos & Dixon, 2002) 
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account for the insurer or government and out-of-the-pocket payments are used to meet 
any gap between premium or tax revenue and expenditure (Mossialos & Dixon, 2002). 
In the purchasing of the service function the pooled resources are transferred to service 
provider on behalf of the population for which the funds were pooled. Many health care 
systems allocate the resources based on political negotiation, historical standard, and 
lowest bid even though they should be allocated according to the health care need of each 
population. This would support the equity and efficiency of healthcare systems 
(Mossialos & Dixon, 2002). 
Three models of healthcare systems can be recognized based on the source of funding of 
healthcare: Beveridge model, Bismarck model and the private insurance model. Funding 
in the Beveridge model is based on taxation and the services are mainly provided by 
public health providers (hospitals, community doctors, etc.) (Lameire et al., 1999). The 
hospitals and clinics are owned, and some doctors are employed by the government. 
However, there can also be private doctors that are paid by the government. Moreover, 
government monitors and controls doctors’ work and fees to high extent (Reid, 2009). In 
the Beveridge mode, the budget of health care is competing with other spending priorities, 
but it offers the access of health care to each citizen of the country (Lameire et al., 1999). 
The Bismarck model is based on a non-profit social or mandatory insurance system that 
is financed with employers and employees through payroll deduction. The services are 
provided by the mix of private and public health providers and the system is regulated by 
the government. However, the system does not cover everyone’s healthcare, which means 
that the difference needs to be compensated with additional private insurance (Lameire et 
al., 1999; Reid, 2009). Nevertheless, Lameire et al. (1999) argue, that the population in 
the countries with Bismarck system, are wealthy enough to be able to invest such money 
on the additional private insurance.  
In the private insurance model, the financing comes from the premiums paid for private 
insurance companies and the health care providers are mainly from private sector. This 
type of model creates inequality between citizens by leaving many citizens, that are not 
able to afford a private insurance, out of the health care system (Lameire et al., 1999). In 
developing countries, out-of-the-pocket models are most common with the lack of mass 
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medical care. The result is that only the people who can afford healthcare, are able to 
receive it (Reid, 2009). 
National health insurance model has elements from both Bismarck and Beveridge models. 
The healthcare providers are from the private sector, whereas the funding comes from an 
insurance program that is run by the government. Each citizen contributes into the 
insurance program. This non-profit insurance program is simple administratively and less 
expensive because the costs can be negotiated to very low level by the single-payer’s 
market power (Reid, 2009). 
2.1.2 Reimbursement Systems 
Reimbursement refers to the payment method and the amount the third-party payers are 
willing to pay for services and products covered for their health plan subscribers. Price is 
the amount that the health care providers charge for providing the product or service for 
members of health plan. Thus, the price needs to be accepted by the third-party payers 
who reimburse the health services and products accepted into the health plan. Otherwise, 
the patient needs to provide a co-payment for the difference. The reimbursement is highly 
regulated in some countries where the reimbursement agents negotiate and set the prices. 
In addition, the use of licenses and quality of products or services are monitored by the 
national regulating agents (Garrison & Towse, 2017). 
The healthcare reimbursement methodologies can be divided in two main categories: fee-
for-service reimbursement and episode-of-care reimbursement. Fee-for-service 
reimbursement is the payment healthcare provider receives for each service offered, 
whereas the episode-of-care reimbursement refers to one payment amount for all the 
services provided related to a condition or disease. Additionally, the reimbursements can 
be further divided into retrospective payment method, where the provider receives the 
payment after the rendered service, and prospective payment, where the cost is based on 
an average rate calculated from historical data (Casto & Forrestal, 2015). 
Prospective payment systems have been established in order to enhance healthcare 
industry’s efficiency through financial incentives to promote a more cost-efficient 
management of healthcare. However, there are some biases imposing these 
reimbursement systems that might benefit the hospitals financially but, at the same time, 
diminish the trust of patients. Upcoding means that the patient is classified to a category 
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that produces a higher reimbursement, whereas cream skimming means either that the 
hospitals select the patients that would be more profitable for them or they choose to 
provide more profitable and less severe treatments. Readmission refers to a practice where 
the same patient is discharged and admitted again after a short period for hospital to 
receive more than one reimbursement for the same treatment (Berta, Callea, Martini, & 
Vittadini, 2010). 
The traditional mechanisms of paying for health care providers are fee-for-service 
(hereinafter referred to FFS), capitation, salary, global budget, and diagnosis-related 
groups (hereinafter referred to DRGs) (OECD, 2016). Physicians often receive the 
payment through salary or fee-for-service per encounter or per procedure (Garrison & 
Towse, 2017). FFS encourages providers to rise their activity-levels which in turn 
increases the associated costs (OECD, 2016). One type of FFS is self-pay in which the 
patient pays a specific amount for each service received directly to the providers. If that 
person then has a health insurance or receives benefit from governmental programs, the 
reimbursement needs to be claimed from that third party afterwards. Otherwise, the 
person needs to pay for that service themselves (Casto & Forrestal, 2015). 
Payment per case is a method where a predetermined rate is defined for a patient group, 
that has similar diagnosis and treatment and, consequently, use of resources and length of 
stay (Casto & Forrestal, 2015; OECD, 2016). The payment is a fixed sum for patients that 
fall into a particular illness category, i.e. a DRG (Garrison & Towse, 2017). Each of these 
groups receive a payment rate where the higher weight refers to more demanding disease 
that require more resources (Casto & Forrestal, 2015). DRGs incentivise the health care 
providers use their resources more efficiently and decrease the average time spent in the 
hospitals. However, health care providers might try to upcode in order to get more 
reimbursements (OECD, 2016). 
Capitation refers to a fixed, per capita amount, that a third-party payer reimburses for the 
health care provider. Capitation is not affected by the volume and intensity of provided 
services nor the complexity of the care. This means that the provider receives the capitated 
rate sum per every individual under the health insurance plan whether or not they use the 
services and regardless of the complexity of disease or illness (Casto & Forrestal, 2015). 
This type of payment helps to control costs, but providers might not deliver the required 
amount of health care that is optimal for patients (OECD, 2016). 
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Global budget, in turn, refers to one amount that is paid for the provider of range of 
services, but is not affected by the actual volume that is provided (OECD, 2016). The 
third-party payer reimburses all the services of multiple providers that are treating a single 
episode of care with one combined payment. A total-episode-of-care is the most inclusive 
version of this and covers all the costs across the continuum of care. However, there are 
fewer comprehensive options in which, for example, only in-patient or ambulatory care 
is covered (Casto & Forrestal, 2015). This type of payment is quite usual in public 
hospitals in many countries and it can help to control the total costs. However, global 
budget might increase the waiting times and create access problems (OECD, 2016). 
The managed care reimbursement method means an FFS reimbursement method where 
the third-party payers control and manage the costs of healthcare and the outcomes of 
care. This type of reimbursement allows the third-party payers to be able to reduce the 
costs of healthcare that it reimburses for the providers while still ensuring a good quality 
of care (Casto & Forrestal, 2015). 
In most developed countries, these systems are established and administered by the 
government, thus called administered pricing and reimbursement systems. Their goal is 
to provide incentives for appropriate provision of services, rewarding productivity as well 
as maintain cost control (Garrison & Towse, 2017). However, the salary system does not 
have any incentive for providing a specific degree of care and FFS might promote cream 
skimming even though the individual elements of care are reimbursed retrospectively 
(Britton, 2015). Furthermore, the reimbursement systems are generally more based on 
cost than value (Garrison & Towse, 2017). Because the payment systems alone can result 
in cream skimming and upcoding, many countries have mixed systems that include 
combinations of the traditional payment systems (OECD, 2016). Nevertheless, no 
universal system has been established and the design process of a feasible reimbursement 
system can be challenging because it should be accountable for quantity, complexity, and 
quality of care (Britton, 2015).  
New payment trends are arising alongside the traditional payment systems that foster the 
outcomes and quality of health care. Add-on payments are paid on top of the main 
payment for a single provider who co-ordinates the care of a chronic patient. Payment-
for-performance (hereinafter referred to P4P) are bonus or penalty payments for meeting 
quality and efficiency targets (OECD, 2016). Compared to FFS, P4P and DRG 
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reimbursement mechanisms are much more complex when functioning properly. P4P and 
DRG both require well-designed patient identification, classification, recording and 
monitoring systems (Ikegami, 2015). To assess the performance, processes, and outcomes 
of care, strict measures need to be in place. (Britton, 2015). Furthermore, upcoding is a 
serious issue in DRG, whereas P4P performance indicators do not necessarily take into 
consideration the individual effect (Ikegami, 2015). Also, not enough evidence is yet to 
support that with P4P it is possible to receive positive results (OECD, 2016).  
Complexities become when the value of care is assessed. On the one hand, individuals do 
not see the cost of service because they do not pay anything at the point of care which 
may lead to care over-use. On the other hand, the providers, especially the competing 
private insurers, seek for the low-risk patients, whereas the high-risk patients are the ones 
seeking for health insurance (Garrison & Towse, 2017). However, these innovative 
payment systems promote for decrease in fragmentation of care, better value and quality 
of care, and controlled costs. Even though, these methods might not improve the broader 
health outcomes, they can help in increasingly better data collection and having more 
informed dialogue with purchasers and providers (OECD, 2016). The establishment of 
electronic medical record (hereinafter referred to EMR) system can promote the accuracy, 
efficiency, and feasibility of any reimbursement system. The real time information would 
benefit third party payers by giving data to determine reimbursement rates and healthcare 
providers to assure the quality of care, outcomes and projecting future resource 
allocations (Britton, 2015). 
2.1.3 Needs in Health Care 
Business models in health care can be divided into three categories: solution shops, value-
adding processes, and user-network models. Solution shops rely on the insight of the 
highly skilled professionals who deliver the value through problem analysis and solution 
offering based on their expertise. As the traditional model of health care, the unique 
services of solution shops attract customers to pay high prices. Value-adding processes 
aim at delivering high quality at low cost through repetitive nature of the processes and 
guaranteed outcome, whereas, in user-network models, the trade happens only among the 
members of that network (Hwang & Christensen, 2008).  
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Value-adding processes enable a more detailed focus in a specific type of care after the 
diagnosis has been done in the solution shop. Additionally, user-network models can 
benefit especially patients with chronic diseases where help can be found from other 
members with similar disease. Affordability, accessibility, and higher quality could be 
further enhanced with technological enablers by simplifying the work of solution shops 
and increasing the predictability of the processes. Ideally, technology can even move the 
work more to patients themselves (Hwang & Christensen, 2008).  
Healthcare systems can reduce social risks and inequality among populations within 
countries. At the time, the health care systems in various countries are undergoing 
changes regarding their policies and regulations (Wendt, Kohl, Mischke, & Pfeifer, 
2010). Various governments, policymakers and countries are emphasizing the need for 
reducing costs of health care (Bodolica, Spraggon, & Tofan, 2016) and are searching for 
new methods that could make the provision of health care more affordable (Shakshuki & 
Reid, 2015). Furthermore, many governmental reforms are focusing on cost and cost 
control (Bodolica et al., 2016; Lameire et al., 1999). The political discussion and social 
conflict are centred around these financial issues regarding the health policies and health 
policy measures (Wendt et al., 2010).  
However, the increased demand for quality and amount of health care does not impose 
any relief for the governments. With the current model of health care, new methodologies 
and innovative technologies are needed for achieving required levels of service. Efficient 
allocation of resources can improve patients’ experience with medical services (Bodolica 
et al., 2016; Shakshuki & Reid, 2015). Moreover, the involvement of health care service 
users into planning processes, would increase their experience and satisfaction. The 
partnerships and collaboration between managers, medical personnel, and patients would 
support the delivery of more effective health care as well as culture of openness and 
mutual learning. However, the implementation of health care systems and processes 
should be left on health care professionals’ judgment and understanding (Bodolica et al., 
2016).  
According to Bodolica et al. (2016), there are two perspectives that explain the drivers 
for involving the public into health policymaking – consumerist and democratic. On the 
one hand, buyer’s choice, preferences, and satisfaction are enforcing the competitiveness 
of health-care providers in the consumerist perspective. On the other hand, democratic 
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perspective emphasizes that everyone has the right to use the public goods but as citizens 
they also have the duty to enhance the public accountability and contribute to societal 
well-being. Consumerism could enhance quality of care when patients’ choice of the 
health care provider increases the competition. The health care providers would become 
more transparent through the increased need for accountability and customer loyalty. 
However, in the existence of blurred professional ethics among different marketplaces 
and doctors’ financial self-interest, the relationship between the patient and the physician 
can become dangerous. This could result in self-diagnosis and auto-medication for 
patients or demanding inappropriate services (Bodolica et al., 2016).  
2.2 Digitalization in Pharmaceutical Industry 
The recent trends in the pharmaceutical industry consist of patient engagement, new 
competitors, focusing on outcome-based care, information availability and improved 
processes. These trends provide opportunities for more personalized solutions, round the 
clock care with real-time help through cross-channel interactions and data-driven insights 
(Chircu et al., 2017). The digital therapeutics can be personalized based on customers’ 
preferences. In order to personalize the healthcare services, the patient is required to 
provide access to personal data which might arise the concern of privacy issues. Hence, 
there is a trade-off between the quality of delivered services and providing personal data 
for the service provider (Lee & Kwon, 2014). The healthcare systems should be 
encouraged for supporting people to reach personalized results that are designed in 
collaboration with the patient and the healthcare provider. This could be achieved by 
enabling the sharing of information between the healthcare provider and the patient as 
well as through more value-based reimbursement systems (Snowdon, Alessi, Bassi, 
DeForge, & Schnarr, 2015).  
The personalization of healthcare and treatment is more probable in digital therapeutics. 
The collection of digital health data enables patients themselves, together with clinicians, 
analyse and further amend the treatment to meet the patients’ needs. In addition, the 
progress of the treatment can be followed with the help of digital health data. Also, when 
the treatment or a therapy session is done via smartphone application, the treatment is less 
time-consuming. People might prefer taking the therapy session at home on their own 
time without the certain stigma that therapy might still have. Although the patient would 
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have a face-to-face therapy session, the collected data acts as a help to personalize the 
treatment and allows the therapist to more precisely consider the relevant issues (Sverdlov 
et al., 2018).  
In the future, value-based healthcare will become more common which might lead 
companies more towards digital therapeutics. In the USA, the regulatory agencies are 
considering increasingly digital solutions, and, for example, diabetes can today be treated 
with digital solutions. The traditional pharmaceutical development process is time-
consuming, whereas the digital platforms enable to launch products more efficiently and 
faster. Clinical trial management can be simplified with the use of digital platforms when 
the recruitment, communication, and patients’ data are digitized. This allows the clinical 
trials to be conducted at home when the patients can be monitored remotely and fewer 
clinic visits are needed. Nevertheless, there are still challenges and uncertainties in the 
reliability and ethics of clinical trials via digital platforms. The authors conclude that 
while there is still much to be done and considered, the potential of digital therapeutics is 
formidable. The enhanced clinical operations, data quality, endpoints and outcome of the 
treatment can be considered as some of the opportunities of digital therapeutics and 
platforms (Sverdlov et al., 2018).  
2.2.1 Digital Solutions and Technologies 
There are many different types of solutions available that differ in disorder focus and 
means of treatment. Examples of technologies and tools used in digital therapeutics are 
games, education material, triggers, monitoring and treatment through sensors, mobile 
apps or VR technology, just to name a few (Kataria & Ravindran, 2018; McSherry et al., 
2018; Tashjian et al., 2017). These solutions allow patients to receive personalized and 
targeted care as well as caregivers to receive real-time information about their patients. 
Moreover, analytics provide the opportunity for predictive, prescriptive, and preventive 
care (Kataria & Ravindran, 2018; Kvedar et al., 2016).  
The current health applications can be divided into consumer-based applications and 
health professional applications. While the consumer-based applications focus more on 
self-management through examining health results and enhancing health through 
personal training, the professional applications content is based on evidence-based 
methods of diagnosis and treatment. Healthcare providers can engage with the patients 
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more effectively with the use of healthcare applications. These can be used as means to 
reach the consumers with a tool that is convenient for them (Snowdon et al., 2015). The 
emerged business models utilize the indication factor and the digital therapeutics can be 
prescribed as monotherapy, the only treatment for one indication, or as pharmacotherapy, 
digital therapy combined with drug. The potential for pharmaceutical company lies in 
combining the drug development with digital technologies and making the treatment 
more effective (Sverdlov et al., 2018). 
A multi-agent system (hereinafter referred to MAS) is a network of entities that work 
together to find solutions to problems that the entity’s capabilities and knowledge would 
not be enough to resolve individually. An agent in the MAS can be software, hardware, 
or human in nature and each of them has unique properties and capabilities such as 
behaviour, data, goals, and motivation. In healthcare, MAS application can provide a tool 
for complex and diverse communication between groups of health care professionals and 
patients and support patients’ independent lifestyle in remote areas. The benefit also lies 
for health care systems when overall costs can be reduced. One example of a MAS 
application is telemedicine applications where the biomedical monitoring remotely via 
sensor nodes in or on body and real-time communication with physician through phone, 
email, or video conferencing is possible. The wearable and implantable sensors record 
historical information, provide insights and report abnormality, and can be used in 
conditions such as diabetes, tumour, cancer, or physical disabilities. Moreover, the MAS 
application can have the functionality of detecting falls and further assistance can then be 
provided (Shakshuki & Reid, 2015). 
Many MAS applications and research focus on fall detection, gait analysis, heart rate 
monitoring using electrocardiogram (hereinafter referred to ECG), pulse oximetry, and 
detecting Parkinson’s episodes and their severity. This type of applications can help to 
maintain an independent lifestyle of the elderly population and disabled individuals. 
Moreover, these could help in cutting down on waiting and processing times for both 
patients and doctors in the healthcare system (Shakshuki & Reid, 2015).  
Remote patient management (hereinafter referred to RPM) in chronic diseases has shown 
positive evidence for the patients. First of all, the RPM technologies can be seen as an 
early intervention and detect decline in patient’s condition before any services are needed. 
When patients need health services, RPM technologies enable the integration of care with 
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exchanging the data between multiple providers about the states of disease. The use of 
RPM increases also patient’s own understanding of the condition and makes them more 
confident in managing the condition by themselves. Throughout the care, the patients can 
be coached and motivated to support patients’ behavioural change and selfcare. It 
supports patients’ satisfaction when a connection is created with the providers and further 
increases trust and sense of security towards caregivers. With the help of RPM 
technologies, the productivity increases when there are less face-to-face meetings and 
documentation becomes more automated. Additionally, medical assistants, community 
health workers, and social workers become more important along the RPM technologies 
(Coye, Haselkorn, & DeMello, 2009).  
Implantable biosensors are the future of measuring metabolic levels of the patients 
without the need for patient intervention and regardless of the patient’s physiological state 
(e.g. sleep, rest, etc.). These sensors are implanted into the human body and require no 
further interaction from the user to operate and can be used, for example, with diabetes 
patients for glucose tracking. MAS applications possess many ethical, technical and 
social design challenges but it could provide an interconnected, real-time support and 
monitoring for entire populations. It can provide an opportunity for a wide-scale health 
care integration where health care services would be available for anyone from anywhere. 
The implantable sensors and wide-scale integrated healthcare systems could result in 
genetic analysis of diseases and detecting and preventing them through the medical, 
historical, and integrated data which could be further used in medical research (Shakshuki 
& Reid, 2015).  
The increasing demand and awareness of quality in health care have created pressure for 
governments to identify health technologies that offer the best value for money (Oortwijn, 
Mathijssen, & Banta, 2010). Health Technology Assessment (hereinafter referred to 
HTA) tool has been adopted by many organizations, such as private companies and 
healthcare providers, for the purpose of gaining a better understanding and more 
information about the way these health technologies are performing (Turchetti, Spadoni 
& Geisler, 2010). This tool assesses not only the cost-effectiveness of the technologies 
but also aids in decision-making processes regarding health care system regulations, 
quality of care assessment, and reimbursement decisions. Because the HTA decisions 
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need to be based on scientific methods and research results, it helps in considering all 
related evidence in a systematic way (Henshall & Schuller, 2013; Oortwijn et al., 2010).  
2.2.2 Pricing Digital Content 
The digital content is predominantly offered for free, because the marginal cost for 
reproducing the digital service or a product is practically zero. However, in the early 
development phase, the fixed costs can be high and thus, many digital service providers 
have developed strategies for receiving revenue (Na, Hwang, Hong, & Lee, 2017). 
Usually, a company in a monopoly situation chooses only one pricing scheme. In 
addition, when a company is introducing a new product or a service, marketing is simpler 
with only single pricing option (Wu, & Banker, 2010). The pricing is affected by various 
parameters, such as demand, value, and even competition. However, the customer 
attractiveness acts as an important determinant in pricing decisions (Lehmann & 
Buxmann, 2009).  
Even though a digital product or a service would be offered free for the users, the 
company is able to generate revenue, for example, through advertising sales (Na et al., 
2017). Additionally, the user can be offered complementary products or premium 
versions in the otherwise free platform (Lehmann & Buxmann, 2009). This freemium 
pricing model enables the customer to use the digital service or product for free as long 
as they like, and the revenue is generated through users that are willing to purchase 
additional products or services. The benefit for the company is in attracting a high number 
of customers by lowering the entry barrier. However, the number of customers that are 
willing to pay, remains low. Thus, it is essential to identify this type of customers in early 
stages and create means to have them stay as well as continue paying (Voigt & Hinz, 
2016).  
The pricing of a digital service or product is usually a single payment, that grants a full 
access, or regular repetitive payments, i.e. subscription fees, that vary in their frequency 
and duration (Lehmann & Buxmann, 2009). Additionally, a usage-based pricing refers to 
a method where, for example, a commission is paid only when the service is used. In a 
two-part tariff pricing the user is charged a subscription fee as well as a price for other 
services, such as maintenance or a single call (Wu, & Banker, 2010). A pricing strategy 
that is based on price discrimination means that the same digital product or service is 
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offered with various prices. The price can simply be based on different customer’s 
willingness to pay, or different customer segments. In addition, there can be different 
prices according to customer’s selection of price-product combination based on factors 
such as time, quantity, or performance. Furthermore, price bundling represents a 
collection of various sub-services from one or more service providers that are determined 
a total price (Lehmann & Buxmann, 2009).  
When a company is willing to acquire a desired customer base, the dynamic pricing 
strategies can be used. One of them is the penetration strategy where lower prices 
compared to competitors attract customers in market entry. When the customer base has 
been generated, the prices are increased. In contrast, skimming strategy is used when a 
company starts with high prices and lowers them in the course of time in order to attract 
customers willing to pay high prices. However, the skimming strategy for digital services 
or products is rarely used (Lehmann & Buxmann, 2009).  
The demographic and lifestyle changes in societies are pressurizing the governments 
deliver high quality health care with reduced cots, while the need for value-based pricing 
and reimbursement is increasing (e.g. Bodolica et al., 2016; Lameire et al., 1999; 
Länsisalmi et al., 2006; Wendt et al., 2010). However, the uncertainties with assessment 
of quality and value in health care still remain evident (e.g. Britton, 2015; Garrison & 
Towse, 2017; OECD, 2016). New health technologies and digital solutions provide 
opportunities for personalization, real-time help, and data-driven insights (e.g. Chircu et 
al., 2017; Kvedar et al., 2016; Snowdon et al., 2015; Sverdlov et al., 2018), and their 
performance and quality are assessed through HTA. Moreover, the decisions regarding 
health care systems, reimbursement, and pricing of digital content can be supported 
through this assessment as well (e.g. Henshall & Schuller, 2013; Oortwjin et al, 2010; 
Turchetti et al., 2010). 
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3 THEORETICAL BACKGROUND 
The theoretical background aims at providing support for the conducted study, and a 
thorough understanding about the existing business environment. The thesis covers case 
companies internationally (the USA and countries in the EU) and they were chosen for 
the purpose of studying and comparing already established digital therapeutics companies 
according to their solutions and treatment possibilities. Moreover, the client company 
operates internationally, and aims at gaining the market access in the USA, Finland, 
Germany, and France. Thus, the introduction of the business environment with regards to 
the health care systems and regulative space in these countries is required for deeper 
understanding.  Lastly, the business models and the choice for VISOR framework as a 
business model ontology is motivated.  
3.1 Health Care in the USA 
The health care system in the United States of America (hereinafter referred to USA) is 
complex and scarce in its nature. Health care is not accessible for everyone, and it is 
mainly covered through private health insurance which, in turn, is mainly offered by the 
employers. Nevertheless, there are around one thousand health insurance companies 
providing these private health insurances, whereas the private managed care sector 
consists of hundreds of licensed health maintenance organizations (hereinafter referred to 
HMOs) and preferred provider organizations (hereinafter referred to PPOs). In addition, 
the government of the USA administers two main public health insurance programs called 
Medicare and Medicaid (Shi & Singh, 2017).  
At present, managed care is the leading health care system existing in the USA. Managed 
care refers to combining the core functions of effective health care delivery for managing 
the utilization and costs of medical services. The managed care organizations (hereinafter 
referred to MCOs), such as HMOs and PPOs, have contracts with both the health care 
providers, as well as the private and public health insurance programs. Then, these 
particular health care providers deliver health care for the managed care plan members. 
Furthermore, the arrangement between the enrolled individual and MCO is called a health 
plan where the reimbursement is mainly based on capitation. In a discounted fee 
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arrangement, the health care providers are promised a patient population in exchange of 
discounted services (Shi & Singh, 2017).   
In the USA, public health care is provided only for specific groups of people such as 
elderly, children and disabled individuals. Furthermore, the community health centres, 
migrant health centres, free clinics, and hospital emergency departments, i.e. safety net 
providers, are targeted to so called special populations which are individuals in the need 
of health care but do not have the required resources. Medicare is one of the public health 
insurance programs that is for elderly, disabled and people with end-stage renal disease 
and it covers hospital care, post-discharge nursing care, hospice care, outpatient services, 
and prescription drugs. The other public health insurance program, Medicaid, covers low-
income adults, children, the elderly, and individuals with disabilities as well as the long-
term care for elderly and disabled individuals (Shi & Singh, 2017).   
Despite these governmental options available, the growing number of poor and Medicaid-
insured individuals create pressure for the safety net providers which are not available in 
every community. Furthermore, many individuals need to acquire separate insurance for 
long-term care because Medicaid covers only a certain population group and Medicare 
does not cover such care. However, the private insurance for long-term care cannot be 
afforded by most of the people. Integrated delivery systems (hereinafter referred to IDSs) 
is a health network consisting of health care providers and organizations that are held 
responsible and accountable for the quality of care. IDSs deliver a continuum of care that 
is more cost-effective and higher quality. The accountable care organizations (hereinafter 
referred to ACOs) are acting under new payment incentives that foster better quality 
outcomes while reducing costs (Shi & Singh, 2017).   
3.2 Health Care in the EU 
In the EU, the individual countries have the main responsibility for organizing and 
delivering health services and medical care. However, the EU has a health policy for 
complementing national policies as well as to guarantee protection of health in all EU 
countries. Additionally, the EU provides funding through some investments programs as 
well as aims at improving the efficiency and accessibility of health care in each member 
state (European Commission, 2019). For the purpose of this thesis, the means of health 
care delivery in Finland, Germany, and France are presented. 
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3.2.1 Health Care in Finland 
In Finland, the health care system is universal, and each individual has the right for social 
welfare and health care services (Ministry of Social Affairs and Health, 2013). The 
municipalities and local authorities are responsible for organizing social and health 
services, and these are mainly provided publicly. However, some private and non-
government organizations complement the service delivery. Thus, the municipalities can 
outsource their services either to another municipality, or private service provider.  
Primary care is offered in municipality health centres, secondary care in central hospitals 
and tertiary care can be accessed in five university hospitals. Furthermore, employers are 
required to organize preventive occupational health care for their employees, but most of 
the employers organize additional medical care in voluntary basis (Ministry of Social 
Affairs and Health, 2019).  
Finnish health care is financed through municipal tax revenues and central government 
subsidies (Ministry of Social Affairs and Health, 2019). The Social Health Insurance 
(hereinafter referred to SHI) is coordinated by the Social Insurance Institution of Finland 
(Kela) and can be divided into medical care insurance and earned income insurance. The 
funding for medical care insurance comes from contributions that are withheld from the 
income, pension, and policy-holders’ benefits (Ministry of Social Affairs and Health, 
2013). Health care services are not free-of-charge and municipalities charge patient fees 
(Ministry of Social Affairs and Health, 2019). However, a maximum amount of paid fees 
has been established to provide free or discounted health care once this amount has been 
achieved by an individual patient. This ceiling applies not only to health care services, 
but also to prescription medicine (Ministry of Social Affairs and Health, 2013).  
The medical care insurance covers tests and treatments requested by private doctors. 
However, the costs are only reimbursed according to the statutory reimbursement rate 
based on DRGs and the excess amount is paid by the patient as an out-of-the-pocket 
payment. Earned income insurance covers paid allowances for instances when employers 
not able to work, such as maternity or paternity leave and sickness (Ministry of Social 
Affairs and Health, 2013). In Finland, the Voluntary Private Health Insurances 
(hereinafter referred to VPHI) are not common and are only acquired for out-of-the-
pocket payments that the SHI does not cover. Furthermore, the VPHI might be duplicate, 
which means that the same care is offered by both public and private health care 
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providers, but private care can be accessed without any waiting time. However, some 
health care services are not offered by the public health care providers and then 
supplementary VPHI covers such services in the private health care. The private insurance 
companies determine the services included in the health insurance and one of the criteria 
is individual’s health history (Alexandersen, Anell, Kaarboe, Lehto, Tynkkynen, & 
Vrangbæk, 2016).  
The main challenges regarding health care services in Finland concern the accessibility 
of health care and the quality of care for elderly people. For solving these issues, a health 
and social services reform has been discussed for over a decade. The goals of the reform 
are to decrease the inequality of people’s wellbeing as well as to provide an equal access 
to high-quality services. However, the final decisions have not yet been made or 
reinforced (Ministry of Social Affairs and Health, 2019).  
3.2.2 Health Care in Germany 
Germany has the oldest SHI system in the world by being the first one ever established. 
The government is not included in the health care delivery and the regulatory details 
regarding health care are issued by the Federal Joint Committee that makes decisions 
about SHI benefits, reimbursement systems and quality assurance (OECD & European 
Observatory on Health Systems and Policies, 2017b). The Federal Joint Committee 
consists of self-governing associations within sickness funds and provider associations. 
However, the state’s own university hospitals and municipalities deliver the public health 
services (Mossialos, Djordjevic, Oxborn, & Sarnak, 2017). Moreover, the states oversee 
these self-governing bodies and are responsible for hospital planning and investments as 
well as medical education (OECD & European Observatory on Health Systems and 
Policies, 2017b). 
In Germany, the health care system is almost universal, and the health insurance is 
compulsory for everyone. The health care is financed through SHI that is provided by 
more than hundred sickness funds. In turn, SHI is funded by contributions from wage and 
pooled together with some tax subsidies in the central health fund. Then, the revenues are 
reallocated into different sickness funds according to the risk of the population groups 
that the sickness fund covers (OECD & European Observatory on Health Systems and 
Policies, 2017b).  
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SHI covers automatically employees that earn less than a certain limit. Through a global 
budget, the SHI compensates ambulatory care, whereas individual physicians receive an 
FFS payment that is based on DRGs. Employees that earn more than the threshold, can 
either stay in SHI voluntarily, or they can choose a substitutive Personal Health Insurance 
(hereinafter referred to PHI). The PHI contributions are based on individual health risk 
and user fees paid for practitioners are usually higher (Mossialos et al., 2017).  
The health care system in Germany is highly accessible by everyone with low out-of-the-
pocket payments and high number of health care providers. In addition, the self-governing 
bodies assure that new decisions in institutions and health care professionals are well-
informed. However, a gap exists between the ambulatory and hospital care as well as the 
primary and specialised care. These differences pose to challenges regarding the 
continuity of care and coordination of services (OECD & European Observatory on 
Health Systems and Policies, 2017b).  
3.2.3 Health Care in France 
In France, the health care system is universal, and all legal residents are covered by the 
SHI. The regional health agencies are responsible for ensuring that health care is provided 
locally and meets the needs of the population. The funding of SHI comes mainly from 
employers and taxpayers’ contributions based on income. Additionally, specific taxes 
have been earmarked for public health care spending (OECD & European Observatory 
on Health Systems and Policies, 2017a).  
The SHI covers a vast array of medical goods and services such as hospital care and 
treatment by both public and private institutions as well as diagnostic procedures, 
laboratory test, pharmaceutical products and medical appliances prescribed by the 
doctors. However, health care services are not free-of-charge and the patients always need 
to pay either a percentage of the service fee or a specified flat rate (OECD & European 
Observatory on Health Systems and Policies, 2017a). Mostly, the payment is received as 
an FFS payment as well as a yearly capitated payment per person of chronic diseases, 
whereas some specialists receive salary from the hospital. In addition, P4P payments are 
received when disease-specific quality targets are met (Mossialos et al., 2017).  
Even though the SHI covers most of the health care, a Voluntary Health Insurance 
(hereinafter referred to VHI) is acquired for complementary purposes. VHI covers out-
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of-the-pocket payments as well as medical goods and services that are not covered by 
SHI. Most of these insurances are acquired from a publicly funded complementary 
coverage. Because most of the people have a complementary VHI, the amount of out-of-
the-pocket payments remain lowest in the EU. However, some population groups do not 
have a possibility for a good, or any, complementary health insurance which creates 
financial barriers for receiving health care services (OECD & European Observatory on 
Health Systems and Policies, 2017a).  
The challenge of the French health care system is in delivering health care for people in 
certain geographic areas. However, the French Ministry of Health has created incentives 
for doctors and other health care professionals for employment in such areas. Moreover, 
the shortage of doctors has resulted in accepting more people in medical schools and the 
roles of health professionals have been extended because of the inequal balance between 
generalists and specialists. Nonetheless, the main challenge remains in delivering quality 
health care for ageing population and people with chronic diseases (OECD & European 
Observatory on Health Systems and Policies, 2017a).  
3.3 Regulations 
In the USA, regulations regarding the digital therapeutics have already been developed. 
The digital therapeutics tools mostly fall into the Food and Drug Administration’s 
(hereinafter referred to FDA) Mobile Medical Applications (hereinafter referred to 
MMAs) group. Under this category, the digital therapeutics tools are classified according 
to their therapeutic benefit, safety, and risk factors, intended use or indication for use 
(Sverdlov et al., 2018). From the legal and regulatory respective, digital therapies are 
considered as Software as a Medical Device (hereinafter referred to SaMD) (De Luca, 
2019). According to Kirisits & Redekop (2013), for a device to be considered as a medical 
device, it has to fulfil two criteria: “it is used for prevention, diagnosis, monitoring or 
treatment of a certain health state; and its primary mode of action is not based on a 
pharmacological, metabolic or immunological process.” (Kirisits & Redekop, 2013, p. 
16).  
Consumers and patients are reluctant to use a medicine when the evidence of the 
effectiveness is lacking, even though it could be beneficial for them. That is why the 
regulatory agencies certify the safety, quality, and efficacy of medicines (Garrison & 
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Towse, 2017). In some parts of the world, digital therapeutics solutions have been 
recognized as digital therapies, i.e. reimbursed, and prescribed by healthcare 
professionals. However, the regulations are still in its infancy in many parts of the world, 
including the EU (De Luca, 2019).  
3.3.1 Regulating Medical Devices in the USA 
In the USA, Federal Trade Commission (hereinafter referred to FTC) has developed an 
interactive tool that can be used in the mobile health application development process for 
analysing federal laws that might be applicable. This tool intends to help companies to 
examine the regulations regarding mobile applications aiming to diagnose or treat a 
disease or a health condition and that gather, produce, or distribute consumer information. 
The general process of determining laws and regulations regarding mobile health 
applications is illustrated in Figure 3 (Federal Trade Commission, 2016). 
Health Insurance Portability and Accountability Act (hereinafter referred to HIPAA) 
covers the privacy and security of personal health information that are applied by the 
Office of Civil Rights (hereinafter referred to OCR). The HIPAA rules concern HIPAA 
covered entities that include health care providers managing electronic transaction and 
health plans as well as health care clearinghouses receiving non-standardized health 
information for processing. Furthermore, a HIPAA business associate is an entity that 
generates, maintains, or acquires protected health information on behalf of another 
covered entity. These entities are required to secure personal health information that can 
Figure 3 Regulative Process for Market Access in the USA (Federal Trade Commission, 2016) 
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be tracked to identify a customer as well as notify the OCR about any breaches. In 
addition, the HIPAA rules give the customers a right for their own health information. 
The FTC Act maintains fair and reliable practice in commerce as well as secures the 
privacy and safety. Moreover, the FTC’s Health Breach Notification Rules requires 
personal health records (hereinafter referred to PHR) providers, PHR-related entities, or 
service providers to notify about PHR information breaches (Federal Trade Commission, 
2016). 
FDA applies the Federal Food, Drug, and Cosmetic (hereinafter referred to FD&C) Act 
for the purpose of controlling the medical devices’ safety and effectiveness. Medical 
applications, that focus merely on self-management or controlling, following, and 
accessing health information, are considered as minimal risk devices and the regulatory 
oversight is not applicable. However, the regulatory oversight applies to a mobile medical 
application that is used in conjunction with a regulated medical device (Federal Trade 
Commission, 2016). Moreover, the medical applications, that would present a high risk 
when working incorrectly, are subject to FDA’s regulatory oversight and the medical 
device needs to be classified according to its risk, indication for use, and intended use 
(U.S. Food & Drug Administration, 2018). 
A list of medical devices is maintained by the FDA and the classification of medical 
devices outlines the regulatory requirements for that general type of device. While Class 
I devices presents the least risk and regulatory requirements, the devices in Class III 
present the highest risk. Moreover, most of the Class I devices are exempt from any 
premarket approval from the FDA. Companies commercializing Class II medical devices 
are required to deliver a Premarket Notification 510(k) and provide proof that the medical 
device is at least as safe and effective as a legally marketed device. Once a letter from 
FDA is received, stating that the device is substantially equivalent, the medical device is 
cleared for commercial distribution. Furthermore, Class III devices are required a 
Premarket Approval (hereinafter referred to PMA) that consists of clinical trials and 
evidence that support the claims made for the device. In addition, the FDA approves the 
medical devices according to the PMA before they can be marketed (U.S. Food & Drug 
Administration, 2018). 
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3.3.2 Regulating Medical Devices in the EU 
In the EU, the medical devices are mainly regulated by national competent authorities, 
but the European Medicines Agency (hereinafter referred to EMA) assesses a portion of 
the medical devices (European Medicines Agency, 2019). A company can market the 
medical device in the EU only, if it has a Conformité Européenne (hereinafter referred to 
CE) mark on the device which can be received by meeting the essential requirements 
requested by the EU Directive and passing the Conformity Assessment (European 
Commission, DG Health and Consumer, 2010). An accredited Notified Body designated 
by each EU member state conducts the Conformity Assessment in order to indicate the 
medical devices’ safety and effectivity according to their intended use (European 
Medicines Agency, 2019). Clinical evaluation is an essential requirement for each 
medical device. The clinical evidence needs to confirm the side-effects as well as confirm 
the said characteristics of the medical device. The member states’ own competent 
authorities are notified by the manufacturer about the clinical investigations (European 
Commission, DG Health and Consumer, 2010). The process of receiving a market 
authorization in the EU is illustrated in Figure 4. 
Figure 4 Regulative Process for Market Access in the EU 
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For the purpose of Conformity Assessment, the medical devices are classified by the 
manufacturer based on their risk, characteristics and intended use. Furthermore, the 
classification specifies the level of control in the assessment (European Commission, DG 
Health and Consumer, 2010). The Class I medical devices pose the minimum risk to the 
patient and the companies can certify them by providing proof of requirement 
compliance, whereas the registration is done with the competent authority. However, the 
Class I medical devices that are sterile or have a measuring function, the Notified Body 
is required to assess the requirement compliance. The Class IIa devices are for short-term 
use, whereas the Class IIb devices may be used for longer than 30 days, and both devices 
pose a medium to high risk to the patient. Furthermore, the Class III devices pose the 
highest risk possible and are being monitored for their lifecycle continuously. All these 
devices are required for assessment by the Notified Body (Max Strålin, 2019). 
In most cases, the Notified Body only assures that the quality management is compiled 
by the manufacturer. However, some of the Class IIa and Class IIb and all the Class III 
medical devices are examined by the Notified Body in accordance with their design and 
assured that they comply with the Essential Requirements as well (European 
Commission, 2017). Once the medical device is approved by the Notified Body, they 
provide a certification that the medical device fulfils the essential and technical 
requirements of the CE directives. Moreover, it makes the company responsible for 
obliging the requirements set by the CE mark. After this, the company is authorized for a 
Declaration of Conformity (www.ce-check.eu). When the CE mark has been certified, 
the company needs to place the CE mark into the product (Valvira, 2017). 
3.4 Business Models 
Several studies and a vast amount of literature covering business models can be found 
(e.g. Bouwman, Nikou, & de Reuver, 2019; El Sawy & Pereira, 2013; Guo, Nikou, & 
Bouwman, 2015; Wirtz, Pistoia, Ullrich, & Göttel, 2016; Zott, Amit, & Massa, 2011;). 
Despite of this, no universal definition of the concept business model has been created 
and often business model is referred to as a tool or a concept rather than a unified theory 
(Lambert & Davidson, 2013). Furthermore, the definition and focus of the business model 
framework highly depend on its purpose, field of the business as well as the researcher’s 
theoretical perspective (Lambert & Davidson, 2013; Zott et al., 2010; Pateli & Giaglis, 
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2004; Shafer, Smith, & Linder, 2005). The vast number of differing definitions of a 
business model create challenges for comprehending the vital components and analysing 
the business models systematically (El Sawy & Pereira, 2013).  
The literature and research regarding the business model conceptualization has evolved 
through time from defining and classifying business models as well as listing the various 
components and describing the different elements of business models to creating business 
model ontologies, applications and conceptual tools. This development has allowed 
researchers to asses and examine the business models and ontologies, whereas the 
businesses have begun to apply them in management and IS applications. Consequently, 
the focus has shifted into building theory and modelling dynamically (El Sawy & Pereira, 
2013).  
Osterwalder and Pigneur (2010) emphasize that in order to discuss business models and 
compare, innovate or even change them it is important to find a business model concept 
that everyone is able to comprehend. However, it is very challenging to create a concept 
that is straightforward, applicable and intuitively comprehensible enough without 
drawing too simple a picture of how businesses function (Osterwalder & Pigneur, 2010). 
In fact, most of the research does not define the concept business model at all or simply 
just list the main components of the business model. The result is that in most research 
the meaning of the concept business model is assumed. Moreover, when the concept is 
defined, the definition refers to another researcher’s definition of the concept (Zott et al., 
2010).  
A business model can be conceptualized through “building blocks” that describe the 
rationale for how the business plans to make profit. These building blocks take into 
account the main areas of a business: customers, offer, infrastructure, and financial 
viability. Thus, the business model acts as a sort of design for a strategy that is put into 
action through organizational structures, processes, and systems (Osterwalder & Pigneur, 
2010). According to Osterwalder and Pigneur (2010, p.14) “a business model describes 
the rationale of how an organization creates, delivers, and captures value”. Shafer et al. 
(2005, p. 202) define business model as “a representation of a firm’s underlying core logic 
and strategic choices for creating and capturing value within a value network”. Bouwman, 
and Haaker and de Vos (2008) focus on the services as well as emphasize that the service 
is rather created and delivered by a network of organizations or companies than by a 
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single organization or company. They define a business model as “a blueprint for a service 
to be delivered, describing the service definition and the intended value for the target 
group, the sources of revenue, and providing an architecture for the service delivery, 
including a description of the resources required, and the organizational and financial 
arrangements between the involved business actors, including a description of their roles 
and the division of costs and revenues over the business actors.” (Bouwman, Haaker, & 
de Vos, 2008, p. 33). 
Morris et al. (2003) categorized the business model concept definitions into three entities 
based on their primary focus. These three categories are economic, operational, and 
strategic where each one is composed of different decision variables. The economic 
category focuses on the rationale in generating profit and comprises decision variables 
such as sources of revenue, margins, volumes, cost structures and pricing methodologies. 
The operational category emphasizes the value creation and the architectural design 
behind it. Internal processes and infrastructure design define the decision variables in this 
category. These are, for example, delivery methods of the product or a service, knowledge 
management, logistical streams, administrative processes, and resource flows. Finally, in 
the strategic category the business model definitions have the focus on the company’s 
position in the market, the company’s interaction between different organizational units, 
and expansion opportunities. How to have the competitive advantage and be sustainable 
are the key questions in these definitions. The decision variables include differentiation, 
vision, values and value creation, networks, alliances and stakeholder identification 
(Morris, Schindehutte, & Allen, 2005).  
According to Morris et al. (2003), the most important category is the strategic one because 
it has the elements that eventually give the rules for capturing value in the company. 
However, in order to be successful, the company needs to be unique in the way it does 
business which means that it needs to have unique architectural design (i.e. operational 
category) or logic of generating profit. This means that eventually a business model is the 
combination of all of these three categories. Based on this, Morris et al. (2003, p. 727) 
proposes a definition that takes into consideration all of these elements: “A business 
model is a concise representation of how an interrelated set of decision variables in the 
areas of venture strategy, architecture, and economics are addressed to create sustainable 
competitive advantage in defined markets.” 
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Wirtz et al. (2016) takes a very detailed view on the concept of business model through a 
literature view by combining different definitions together. In general, a business model 
takes into consideration all the components within a company and creates value through 
the frames of a business, its processes and architecture. Simply put, business model 
describes the company’s most relevant activities, i.e. in which ways the company’s value-
added component is used to produce their products and services. In addition, business 
model should aim at creating and, more importantly, securing the competitive advantage 
by taking into consideration the strategic, customer and market components as well. Wirtz 
et al. (2016) emphasizes the importance of dynamic perspective which means that the 
company should continuously evaluate the internal and external changes that might 
contribute to the need of modification of the current business model.  
Chesbrough (2010) has defined business model through various functions it is comprised 
of. First of all, a business model expresses the company’s service and/or product that 
creates value for the customer i.e. the value proposition. Then, the business model should 
recognize the customers that would find the service and/or product useful (i.e. market 
segment recognition) and for what kind of purpose (i.e. revenue generation mechanism 
specification). Business model should also specify the structure of the value chain that is 
expected to produce and distribute the service and/or product. Complementary assets 
supporting the different actors in the value chain are also specified. A business model 
needs to further specify in detail the revenue mechanism(s) which determine how the 
company is paid for the service and/or product. The cost structure and profit potential 
estimations are a part of a business model as well. In addition, the business model 
describes the company’s position within the value network that links the suppliers and 
customers as well as identifies potential complementors and competitors. Finally, the 
business model defines the competitive strategy that enables the company to gain and 
hold advantage over the competitors (Chesbrough, 2010). 
Some argue that a business model can directly be associated with the company’s strategy 
(Teece, 2010; Lambert & Davidson, 2013; Cortimiglia, Ghezzi, & Frank, 2016), while it 
is strongly emphasized that it is not a strategy itself (Shafer et al., 2005). Business model 
acts as a middleman between the strategy and operational function. It defines and creates 
the working rules for how to achieve the objectives of a strategy (Cortimiglia et al., 2016). 
It is argued that a business model is mostly a planning tool or a communicator that a 
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business can use to evaluate and address its strategic choices chosen to take in a new 
business venture (Lambert & Davidson, 2013; Shafer et al., 2005). Then again, a business 
model can be used in mapping the existing business to answer concerns that might require 
reinvention (Jeansson et al., 2017; Johnson, Christensen, & Kagermann, 2008; Morris, 
Schindehutte, & Allen, 2005). Furthermore, many of the definitions put their emphasis 
on the value and creation of that value (e.g. Teece, 2010; Osterwalder & Pigneur, 2010; 
Shafer et al., 2005).  
The importance of business models can especially be noticed in value creation of new 
technologies. The way a new technology is commercialized by the company further 
defines how much it creates value. In other words, the same technology can have different 
results depending on the business model (Chesbrough, 2010). Interestingly, value and 
creation of value does not necessarily need to be seen through gaining money. Value 
creation can also mean social and economic value. Thus, a new business model can aim 
at creating societal wealth such as reduce poverty (Zott et al., 2010). 
Even though a business model can help the decision makers to evaluate and communicate 
strategic choices, it is similarly vital to understand the consequences of applying the 
business model in a wrong way. A business model’s core logic should be based on tested 
and correct expectations about the future, i.e. the cause-and-effect relationships in the 
business model should be well supported and logical in order to create strategic choices 
that are internally consistent and support each other. Also, the strategic choices should be 
considered holistically in every aspect of a business model and not solely considering one 
aspect of it (e.g. value proposition) to create a realistic picture of the potential success. In 
addition, it is important to put the same amount of effort in the value creation part as in 
the value capture part for also capturing financial returns from the created value. Finally, 
the business model should consider the changes in the value network and not assume that 
it remains unchanged in the future (Shafer et al., 2005). 
The increasing popularity of eBusinesses, has grown the need and interest towards 
Business Model Innovation (hereinafter referred to BMI) in general (Pateli & Giaglis, 
2004). BMI is seen as an innovation that focuses on the business model itself. The current 
studies regarding BMI have focused on two separate approaches: business model design 
and business model development. Business model design refers to creating a whole new 
business model from scratch, whereas business model development concentrates on 
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improving the existing business model (Cortimiglia et al., 2016). However, the concept 
of BMI differs in its definition between researchers and the research is quite dispersed 
and industry specific. In addition, there is no clear understanding about BMI’s impact on 
company’s performance and innovativeness (Bouwman, Nikou, Molina-Castillo, & de 
Reuver, 2018).  
In health care, the business models in different organizations are highly connected to each 
other and adding a new component to a single institution’s business model can be 
challenging. Additionally, policies and regulations can restrict BMI or make it too 
expensive to carry out or maintain (Hwang & Christensen, 2008). Furthermore, 
regulations can slow the BMI process and might limit people and health care professionals 
to even start the change. However, the organizations seek for benefits that improve 
efficiency of internal operations as well as the quality of care (Länsisalmi et al., 2006). In 
fact, the benefit of BMI lies in realizing hidden efficiencies and saving costs (Hwang & 
Christensen, 2008). Through BMI, the patients can benefit from enhanced health care and 
less suffering due to illness (Länsisalmi et al., 2006).  
3.4.1 Business Model Ontologies 
Many business model ontologies have been developed based on various needs and for 
different fields of business. Three widely used business model ontologies are STOF, 
Business Model Canvas, and VISOR. Bouwman et al. (2008) reviewed literature about 
the concept of a business model as well as the components included to the concept. They 
concluded that, in fact, the various different classifications of the components show that 
there is no shared framework of a business model which resulted in a creation of their 
own approach. This approach aims to emphasize the services, organizational networks, 
and innovation/emerging service ideas. This STOF model has its focus on four domains: 
service, technology, organization, and finance (Bouwman, Haaker, & de Vos, 2008). 
Osterwalder and Pigneur (2010) have developed a business model concept that can be 
used in mapping not only the organization’s existing business model but also that of 
competitor or any other organization. The tool, Business Model Canvas, helps 
organizations in business model innovation by creating an overall picture of the company 
and describing the logic behind creating value for customers and the company. 
Osterwalder & Pigneur (2010) identify customers, offer, infrastructure, and financial 
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viability as the four key areas of a business. Based on these areas, the Business Model 
Canvas (see Figure 5) has been divided into nine building blocks that are explained in 
more detail in Table 1.  
The main driver for a business model design differs between companies. A company 
might have recognized an existing but unanswered need in the market that should be 
Table 1 Components of Business Model Canvas (Osterwalder & Pigneur, 2010) 
Figure 5 Business Model Canvas (Osterwalder & Pigneur, 2010) 
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satisfied, or they want to introduce new technologies, products, or services to the market. 
Furthermore, the company is willing to develop, disrupt or change the market with an 
improved business model or they want to establish a whole new market. In the already 
established companies where the organizational structures and existing models already 
exists, the reasons differ to some extent. At times, the company might be facing a crisis 
with an existing business model which forces them to react to the situation with a new 
one. The business environment is changing constantly which might lead the company to 
adapt into the environment with altering, developing, and supporting the existing business 
model. Similarly, the established companies need to consider their business model’s 
viability when introducing new technologies, products, or services into the market. 
Finally, the exploring and testing of new business models in the process of preparing for 
the future might result in replacing the old business model with a new one (Osterwalder 
& Pigneur, 2010, p. 244).  
El Sawy et al. (2013) wanted to unify the different business model components that have 
been discussed in the literature. They found out that there are five broader categories in 
which the business model components can be categorized. The five categories are: “Value 
proposition”, “Interface”, “Service Platform”, “Organizing Model” and “Revenue 
Model”. This VISOR model was not only created in attempt to unify the various business 
model concepts introduced throughout the years but also to further include the key 
elements that have not yet been considered (e.g. user experience and interface factors) 
into the model. 
The VISOR model (see Figure 6) describes the actions a business takes for answering 
customer needs by creating and delivering the best value with the most cost-effective 
approach. Therefore, in a profitable business model the components have been aligned to 
provide the best value proposition that the customers are prepared to pay the maximum 
amount possible. This is accomplished through optimizing the combination of interface 
experience, service platforms and the organizing model which, in turn, results in 
minimum costs possible to provide that service. The VISOR components are described 
in more detail in Table 2 (El Sawy et al., 2013).  
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The Business Model Canvas focuses on analysing a certain business as a whole whereas 
the VISOR framework considers the digital platforms, digital services, and digital 
economy (Nikou, & Bouwman, 2017). Furthermore, the VISOR model has been 
considered as a framework to capture the digital business model rather than a traditional 
business model. In a digital business model, the value dimensions are profoundly altered 
by triggers arisen from digital technologies and the value is created through the subscribed 
users. Moreover, the value is established in use and digital platforms need to have 
balanced incentives for numerous organizations and individuals involved participant in 
Figure 6 The VISOR Model (El Sawy et al., 2013) 
Table 2 VISOR Model Components (El Sawy et al., 2013) 
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an ecosystem (Remane, Hanelt, Nickerson, & Kolbe, 2017). In addition, the VISOR 
framework aids in studying and evaluating thoroughly the various aspects of the digital 
models supporting further analysis. This unified framework aims at providing a shared 
language for experts from various fields (El Sawy et al., 2013). Nikou and Bouwman 
(2017) used VISOR ontology in analysing mobile health care and well-being services and 
it was concluded as a suitable one for realizing the relationships between different 
business model components in the health and wellness applications’ domain. Thus, for 
the purpose of this thesis, VISOR framework is used as a basis for illustrating, comparing, 
and otherwise researching different business models in the digital therapeutics space.  
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4 RESEARCH METHODOLOGY 
The research methodology chapter aims at motivating the chosen research and data 
collection methods by describing the various existing possibilities. Then, the research 
methods chosen for the purpose of this thesis are described and the support for the 
research objectives is validated. Furthermore, the sample and methods for analysing the 
data are presented.  
4.1 Research Methods 
Quantitative research focuses on explaining, describing, and forecasting through 
measuring the area of interest. The data collected is usually coded, classified and cut to 
numbers for the purpose of transferring it to a further statistical analysis. The most 
commonly used data collection method in quantitative research is a questionnaire. In 
comparison, qualitative research aims at acquiring an in-depth understanding and 
building theory based on the acquired information (Sachdeva, 2008). Qualitative 
research, most importantly, studies the purpose of people’s lives in their real-world 
settings and describes their opinions and perceptions in a study. The focus is on the 
contextual conditions in the real world by providing perspectives from existing or new 
concepts for helping to explain social behaviour and thinking. The qualitative research 
gathers the data from multiple sources of data instead of depending on a single source 
(Yin, 2015).  
Case study is a research methodology that refers to a combination of interviews as well 
as history analysis and examination. The information is obtained from several sources of 
data for the purpose of acquiring multiple perspectives about e.g. organization, process, 
or event. Case studies can be single or multiple-case studies and rely on previously 
constructed theoretical propositions (Sachdeva, 2008). Multiple-case study means that 
various cases are analysed for the purpose of understanding the similarities and 
differences between the cases (Baxter & Jack, 2008). The aim is at creating, explaining, 
or analysing theory through mapping existing designs, structures, and features in a 
selected context. The chosen cases are used as means to study particular business-related 
phenomena and further develop to theoretical hypotheses that could be examined and 
generalized to other business contexts or to theory. Thus, the selected cases should be 
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sufficiently similar to create new theory or test the existing one or assure the balance of 
difference and similarity of the cases to make comparisons (Eriksson & Kovalainen, 
2008).  
4.2 Data Collection Methods 
Nowadays, there are an extensive amount of electronic material on the Internet that is 
used for academic research purposes. In the qualitative research, three main categories of 
electronic research can be identified: research literature in electronic media (e.g. working 
papers, conference papers, articles, etc.), existing electronic materials (e.g. annual reports, 
web pages, blogs, etc.), and materials generated for the objective of a particular research 
project (e.g. email interviews, electronic focus groups, etc.). This electronic material can 
be searched from the Internet with the help of search engines (e.g. Google and Yahoo!) 
and relevant key words. However, it is essential for the researcher to be able to evaluate 
critically the electronic material used. For example, the researcher can evaluate the 
electronic materials’ currency, purpose, author, and accuracy in order to create an 
understanding about the relevance and credibility of the material (Eriksson & Kovalainen, 
2008).  
Interview is a qualitative data collection method that aims to gather insights and learn 
about the world of others. The research interview can be divided into three categories: 
structured interviews, semi-structured interviews, and unstructured interviews. In a 
structured interview, the interviewer asks the same predefined questions from each 
interviewee and accepts only a limited amount of response categories. This type of 
interview helps in the process of analysing the questions because it is less time-consuming 
and readily categorized. In contrast, the unstructured interview is based on a conversation 
about a given subject between the interviewer and the interviewee. However, the 
comparison of data can be difficult because the obtained information and discussed 
subject can vary substantially. In the middle of these two methods lies a semi-structured 
interview. It consists of a sequence of themes that are covered during the interview and 
the interviewee leads the conversation towards them. This helps to achieve the same 
theme between each interview and help in the analysis of the data (Qu & Dumay, 2011; 
Wilson, 2016).  
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For a face-to-face interview, problems with time and finance can occur, if the interviewee 
and the interviewer are not situated geographically close to each other. However, the 
technological changes have provided online interviews as an alternative for this more 
traditional interview method. Online interviews can be conducted as focus group or one-
on-one interviews as well as real-time or non-real-time interviews. Skype can be used as 
an instrument for interviewing as it provides the opportunity for audio as well as video. 
In addition, the interview can be recorded through the program (Janghorban, Roudsari, & 
Taghipour, 2014).  
4.3 Research Method Used  
In order to find answers to the first research question (RQ1: What kind of business 
environment exists for the client company?) a literature review has been done to provide 
insights about the existing trends and factors that affect the business environment of the 
client company. Additionally, these factors influence on the market entry decisions of the 
digital therapeutics solution.  
For the purpose of answering the other research questions, the qualitative research method 
has been chosen. A qualitative research method allows an in-depth understanding about 
the existing business models for developing a feasible one for the client company. More 
specifically, for the attempt to answer the research questions two (RQ2: From the 
business model perspective, what type of characteristics arise in existing digital 
therapeutics companies?) and three (RQ3: Which of these characteristics are feasible in 
the client company’s business model?), a multiple-case study approach has been chosen. 
Through a multiple-case study, similarities and differences between existing business 
models of the case companies can be discovered. Furthermore, the similarities between 
the client company and case companies’ solutions can be identified in order to choose the 
feasible characteristics of the business model. The choice of using the multiple-case study 
supports the testing of existing theory to real-world cases as well as applying it to other 
business contexts.  
To support the research question four (RQ4: Which characteristics are perceived 
important by different stakeholder groups within and outside the client company?), in-
depth interviews are conducted to receive information about stakeholder groups’ insights 
for developing a business model. The semi-structured one-on-one interviews are 
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conducted as an online interview due to geographical restrictions between the interviewer 
and the interviewees. The program used is Skype for Business for conducting a real-time 
interview, whereas the interviews are recorded using the recording function in Skype for 
Business and transcribed afterwards. The interviewees are sent information about the 
project and digital solution being developed. In addition, they receive a video that 
illustrates the outlook and functionality of the digital solution. The interview questions 
(See Appendix 1 and Appendix 2) are provided for the interviewees beforehand in order 
to receive more specific insights.  
4.3.1 Sample 
A sampling procedure used in a qualitative research called purposive sampling was 
chosen for this thesis. Purposive sampling refers to researcher deciding cases with a 
particular objective in mind or researcher relying on an expert’s judgment of selecting 
cases. This type of procedure can be used in selecting exceptionally informative and 
unique cases; in selecting participants from a remote or specialized population; or in 
finding specific types of cases for thorough examination (Mohd Ishak & Abu Bakar, 
2014). In the research, the researcher has relied on the judgement of two client company’s 
experts which have selected the case companies as well as the interviewees to fit the 
purpose of this study. The five case companies represent the digital therapeutics 
businesses, whereas they differ in their developed solution’s focus of treated condition 
and used technology. Thus, they are in balance in their similarity and difference for 
creating comparisons. Moreover, the eight interviewees were chosen to represent 
different stakeholder groups based on their expertise in different fields of business. 
Furthermore, the interview questions were sent to four people that are working closely 
with the project for replying in written format. This allows gathering insights and 
perceptions from various points of view.  
4.3.2 Data Analysis Method 
Coding serves as an organizing tool for systematically review the collected data and 
discover links between the concepts and experiences. These codes are allocated to specific 
sentences, paragraphs, or words that correspond predefined concepts while securing the 
context where they appear (Bradley, Curry, & Devers, 2007). The interview questions are 
developed through the VISOR framework. Thus, the pre-defined concepts, taxonomies, 
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and themes guide the interview for gaining more understanding about the specific 
characteristics that are viable for business model generation. The transcribed interviews 
are analysed by coding the recurrent concepts, characteristics, and taxonomies under 
themes based on VISOR framework. The NVivo software is used for storing and coding 
the interviews.   
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5 CASE INTRODUCTIONS 
The information about the case companies are acquired from their websites and through 
interviews published on the Internet. In this chapter, the client company and five digital 
therapeutics case companies are introduced.  
5.1 Client Company 
The client company is a pharmaceutical company operating in a global market that 
develops, manufactures, and markets human and veterinary pharmaceuticals and active 
pharmaceutical ingredients. Continuous development of new drugs and treatment 
methods are a key part of the company’s operations. The main customers are healthcare 
service providers and professionals as well as consumers who own pets. For the client 
company, the evidence-supported possibilities of digital therapeutics have created an 
opportunity to develop a digital therapeutics solution of their own. The solution being 
developed is targeted for treatment of chronic low back pain with the use of VR 
technology. The individuals who suffer from chronic low back pain experience a difficult 
combination of subjective physical feeling and mental locks and fears. Hence, the digital 
therapeutics solution aims at activating and encouraging the patients for motion that 
exposes them to the pain and further teaches them to tolerate it. This will help the patients 
to function in their everyday life with more ease and in improved mental state.  
The solution is being developed by a partner company because the client company does 
not have the expertise in developing software. However, a multidisciplinary team that has 
consisted of the client company’s own staff as well as expertise acquired from outside 
has been involved in the development of the solution based on customers’ needs. The 
customer needs have been obtained through patient interviews and one of the key aspects 
of the solution is mentoring the patient throughout the process. Mental aspects are seen 
equally important as the physical ones and therefore the initial screen of the solution is a 
calming place where the patient can relax before entering the gamified exercises. The idea 
of gamification is to engage the patients in the exercises and motivate them to continue 
through adjusting the difficulty level according to the patients progress as well as 
rewarding them.  
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5.2 Case Companies  
The five case companies have been chosen for the purpose of analysing the companies 
that have already developed such digital solutions. The data of the case companies is 
collected from existing electronic material with the use of search engine Google. The 
main source of data is the websites of the case companies. However, some interviews 
regarding the case companies found from other websites will be used as a source of data. 
5.2.1 Kaia Health 
Kaia Health is a German start-up founded in 2016 by Konstantin Mehl and Manuel 
Thurner. The company has its headquarters in Munich, Germany along with an office in 
the New York City. Company’s solutions focus on the treatment of chronic back pain and 
COPD which are offered in a healthcare platform for patient’s own device. Kaia Health’s 
core is the use of innovative technology and artificial intelligence in their applications. 
The applications have been developed in an interdisciplinary team with experts in various 
medical fields. As a result, a mind-body approach has been developed that includes not 
only the physical exercises but also a mental coach encouraging the patient along the 
process (www.kaiahealth.com).  
Kaia Health’s product portfolio includes Kaia Backpain application, Kaia COPD 
application and Kaia Personal Trainer application. Additionally, iPhone users have the 
access to a Kaia Motion Coach that uses the smartphone’s camera to track the patient’s 
movement to confirm the exercise is done correctly as well as counts the number of 
repetitions. Furthermore, Kaia Blue is an application for organizations to treat their 
employees’ musculoskeletal (hereinafter referred to MSK) pain. It is promoted to reduce 
the organization’s costs whilst increasing the working years of the employees. The 
products are CE marked in the EU and certified as Class I medical device. The company 
is in the process of being certified in the USA but has not yet received the FDA clearance. 
However, the company is performing clinical trials in order to receive evidence-based 
results to support the development of their products. Kaia Health has made 
reimbursement deals with German insurance companies which means that the application 
is free for the subscribers of the insurance (www.kaiahealth.com).  
J. Vilponen: Digital Therapeutics Solution and Business Model Creation 
47 
 
5.2.2 XRHealth 
XRHealth was founded in Israel in 2016 by Eran Orr and now they have offices in the 
USA and Israel. As a medical device company, the focus is on motor, cognitive, physical, 
psychological, postural ability, pain assessment and treatment. The solution combines 
medical application with data analytics in an XR (virtual reality and augmented reality) 
therapeutic platform. The patient’s data about interaction with virtual objects in virtual 
environments is collected and further analysed by artificial intelligence (hereinafter 
referred to AI) cloud computing algorithms. The real-time analytics enable the clinics and 
patients to measure and follow the progress over time (www.xr.health).  
The products of XRHealth have been categorized as VR Portal, AR Portal, Data Portal 
and External Control. The VR Portal and AR Portal are platforms that contain several 
applications for different purposes. However, the AR Portal is still on the development 
phase and does not contain any application yet. In contrast, the VR Portal has gamified 
applications in three categories: Motor, Pain Management & Stress Relief, and Cognitive. 
Additionally, the company has opened the platform for third party developers whose 
applications are included in the platform as well. The applications are presented more 
detailed in Table 3 (www.xr.health).  
The Data Portal is an analytical tool that provides insightful data about each completed 
session. When the AR Portal is used in a clinical environment the clinician can access the 
Table 3 XRHealth's Products (www.xr.health) 
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patient data in the External Control platform. In the platform, the clinician can also 
remotely control the intensity of the exercise based on patient’s needs or mirror the 
patient’s VR headset (www.xr.health).  
As a first certified virtual reality medical company, XRHealth has received both FDA and 
CE registration for medical applications. According to their websites, two of their 
applications are classified as FDA registered medical devices whereas rest of them are 
waiting for registration. Thus, their medical applications are currently distributed in the 
USA and Israel and wellness applications are distributed in the USA, Europe, Australia 
and Israel. There can be found a clinical evidence section in the company’s website where 
independent articles and researches about the use of VR in healthcare have been listed. In 
addition, the company is performing clinical studies in the USA. XRHealth has received 
a CPT code for its devices and presumably some insurances and health plans in the USA 
reimburse the medical applications but there is no clear indication about that 
(www.xr.health).  
5.2.3 MindMaze 
In 2012, as a result of a spinoff from the Ecole Polytechnique Fédérale de Lausanne in 
Switzerland, the company MindMaze was founded by the current CEO Tej Tadi. 
Company’s headquarters is still in the city of Lausanne, Switzerland but they also have 
offices in San Francisco, the UK, Germany, France, and Romania. With the expertise of 
a multidisciplinary team the company focuses on neurorehabilitation through technology 
based on virtual environment. The focus of their solutions is in helping patients that suffer 
from stroke, but the benefits have been discovered for other neurological conditions, such 
as Parkinson’s, traumatic brain injury, multiple sclerosis, and cerebral palsy, as well 
(www.mindmaze.com).  
MindMaze has a variety of innovative technologies and initiatives under development but 
this thesis will focus on their MindMotion product line. The MindMotion PRO is a 
neurorehabilitation device which intended use is after a stroke. It can be used while the 
patient is still in bed which enables the early intervention. The device consists of 3D 
motion tracking camera that simulates the patient’s movements onto 3D avatar that is 
shown on the patient screen. In addition, a separate monitor for therapist allow him or her 
to assign and monitor the therapy sessions (www.mindmaze.com).  
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The MindMotion GO is designed for utilization in a clinical environment and focus on 
improving the motor and task functions through gamified activities related to 
neurorehabilitation. The therapist is the facilitator of the exercises by deciding the body 
part exercised, setting up the length of the exercise as well as the difficulty level of the 
exercise. The exercises are based on a 3D virtual environment that uses a 3D motion 
tracking camera and gives real-time visual and audio feedback. Both products are CE 
marked and approved for use in European clinics and hospitals. Furthermore, they are 
cleared by the FDA and thus, can be marketed in the USA as well (www.mindmaze.com). 
However, MindMaze’s CEO perceives the reimbursement of medical devices irrelevant 
(Knowles, 2019).  
5.2.4 SilverCloud Health 
SilverCloud Health was founded in 2011 and is headquartered in Boston, USA with two 
additional offices in the UK and Ireland. With over 15 years of research, the company has 
developed a digital mental health platform that is based on cognitive behavioural therapy 
(hereinafter referred to CBT) (www.silvercloudhealth.com). CBT focuses on changing 
the behavioural and thinking patterns by presenting different coping skills and strategies 
(Armstrong, 2018). The platform includes over 30 programs targeting various mental 
health issues affecting people in different life situations. One program generally consists 
of 7-8 40-minutes long modules that are recommended to complete once a week. A health 
care provider assigns a personal supporter for each patient as well as decides, together 
with the patient, a most suitable program. In Table 4, the programs are illustrated and 
described in more detail (Health in Mind, 2014).  
Table 4 SilverCloud Health's Programs (www.silvercloudhealth.com) 
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The SilverCloud Health’s platform is registered as a medical device and is cleared by the 
FDA as well as possesses a CE mark. In the UK, the platform can be accessed for free 
through the NHS system (www.silvercloudhealth.com). However, the access for the 
platform can only be granted with the permission from the doctor (NHS, 2018). In 
addition, the platform is available for particular universities through partnerships with 
some US insurance companies (Armstrong, 2018). 
5.2.5 Happify 
In 2012, Tomer Ben-Kiki, Ofer Leidner and Andy Parsons founded Happify that has the 
headquarter in the New York City. The company’s product is a wellness application 
focusing on improving mental health through positive psychology, mindfulness, and 
CBT. This self-care tool consists of over 60 4-week programs ranging in various themes. 
The programs are built from approximately 300 guided meditations and more than 3000 
activities and games (my.happify.com). The company is seeking for clearance from the 
FDA but has not yet received it. However, they are performing clinical trials to gather 
evidence-based data to support the development of their solutions (O'Brien, 2019).  
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6 RESULTS 
This chapter presents the results attained from the multiple-case study as well as the in-
depth interviews. The results are presented through the VISOR framework that has been 
the basis of the entire study.    
6.1 Multiple-case Study 
The multiple-case study is conducted in order to find a feasible business model for the 
client company’s digital therapeutics solution that is under development. The need for the 
development of a business model has risen from the novelty of such a business model for 
the company and thus, existing business models in the digital therapeutics field are 
studied. 
6.1.1 Kaia Health 
Kaia Health’s business model is depicted in Appendix 3 with the use of the VISOR 
framework. Kaia Health’s value proposition for an individual lie in the convenience of 
the application since the daily 15-minute-long exercises can be done at home with 
patient’s own device. The value proposition for the businesses is the cost reduction of 
employees’ health and risk reduction of employees’ missing working days. Monitoring 
and analysing the progress motivates both individuals and businesses. Additionally, the 
Motion Coach confirms that the exercises are done correctly, safely, and sufficiently 
(www.kaiahealth.com).  
The Kaia Health’s customer segments can be divided into B2C and B2B customers. The 
Kaia Back Pain application is targeted to individuals that suffer from chronic back pain, 
whereas the Kaia Personal Trainer application is for any individual interested in 
exercising at home. Alternatively, the Kaia Blue application is targeted to businesses 
where the end-user is the employee of those companies. Moreover, since the application 
is covered by some of the German private insurance companies, can these companies be 
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considered as customers of Kaia Health and subscribers of the insurance as the end-users 
(www.kaiahealth.com).  
The applications are based on non-medical and multimodal therapy where mindfulness 
and mental exercises are combined with physical ones. In addition, the application entails 
optional mentoring via chat with dedicated coaches and education about the condition the 
application focuses on. Compared to conventional therapies, all of this is achieved with 
less effort and time. The treatment is personalized according to patient’s level and 
progress. These are measured with the help of AI technology as well as questions about 
patient’s own perception of their level (e.g. patient’s experienced pain level) 
(www.kaiahealth.com). 
The interface is easy to use, and the interaction is maintained through social media 
platforms such as Facebook, Instagram, and Twitter. In both application stores (i.e. App 
Store for iOS and Play Store for Android) customer reviews have been responded by the 
developers and can help them develop further their application. Through the application’s 
chat function, the patients can be in contact with a real-life coach. Otherwise, the patients 
download the application, make the purchase, and start the exercise by themselves and 
without any assistance from the company. For businesses, Kaia Health provides the 
service for initiating the treatment by helping to recognize employees that would need 
such a treatment as well as implementing a marketing campaign to reach users within the 
company. In addition, they offer maintenance services of the application 
(www.kaiahealth.com). 
Interface’s aesthetics have been considered and from a customer perspective, it has fact-
based instructions as well as step-by-step guides for the exercises. Progress analysis and 
monitoring provides data that is used further to personalize the service with AI 
technology. Service platform is a closed software, but it is supported by different 
operating systems. The Kaia Back Pain application and Kaia Personal Trainer application 
are available for download in the Google’s Play Store or Apple’s App Store depending 
on the operating system on the patient’s device. This can be recognized as the main 
channel of distributing the application. However, the Kaia Blue application is promoted 
on their websites without any indication for opportunity to purchase the product. Thus, it 
is most probably available by contacting the company (www.kaiahealth.com). 
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The application can be used by the patient’s own device and through a free trial period, 
can be accesses by everyone. However, after that period, only the subscribers are able to 
access the content. Moreover, since the application is reimbursed with some of the 
German private insurances, the subscribers of that insurance have access to the 
application for free. Kaia Health’s key activities focus on the platform management 
including activities such as the maintenance and development of platform as well as 
platform promotion. In addition, they need the evidence-based results for promoting the 
platform for patients and thus need to conduct clinical trials (www.kaiahealth.com). 
Kaia Health’s key partnerships include the medical professionals that help in developing 
the exercises to meet the patients’ needs. By partnering with medical professionals, the 
company can acquire human resources and capabilities they might lack themselves. Kaia 
Health’s partnerships with German insurance companies offers the subscribers of the 
insurance an opportunity for reimbursement. Furthermore, the partnerships with other 
private companies have allowed an access to new customers and generated funding 
(www.kaiahealth.com). 
In the knowledge-based industries the key resources are human resources, and this is the 
case with Kaia Health as well. Their applications have been developed with a well-
designed interdisciplinary team and continuous development requires various experts 
from different fields. As a start-up company, the company needs financial resources for 
conducting clinical trials to receive evidence to support their development process. They 
have successfully raised funding already but, most certainly, are continuously searching 
for more (www.kaiahealth.com). 
The revenue is generated through subscription fees for the application. In the B2C sales, 
the pricing mechanism used is list pricing, i.e. fixed prices for individual products. In the 
Kaia Back Pain application, the patient can access the exercises for free in a seven-day 
trial period. After this, the patient needs to choose from three different option of 
subscription: 32,99 € per quarter, 51,99 € per half a year or 77,99 € per year. Other 
applications’ prices could not be researched because of the non-availability in the Finnish 
app store. In the B2B sales, the prices are most probably negotiated between the 
companies because the data is not available on the website. However, they emphasize that 
the payment is per active user. The reimbursement in some German insurance companies 
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must influence the prices compared to other companies thus making it customer segment 
dependent (www.kaiahealth.com). 
The cost structure of Kaia Health is leaning towards a value driven instead of cost driven. 
The application focuses on generating personalized value for the customers more than on 
minimizing the cost of delivery. The costs include people, R&D activities, and 
maintenance of the application. The cost advantages can be described as economies of 
scope because the same distribution channels and marketing activities apply to company’s 
product variety (www.kaiahealth.com). 
6.1.2 XRHealth 
XRHealth’s business model is described in the Appendix 4 by using the VISOR 
framework. XRHealth’s value proposition is the personalization of treatment through 
real-time data analytics and progress monitoring. The value is generated through 
gamification of exercises which ensures the longer and more intense engagement of 
patients in the treatment. Moreover, the company highlights the patient satisfaction and 
user-friendliness of the application. The use of application can result in cost reductions 
for the clinics, patients as well as the pharmaceutical companies. By using the calculators 
provided on their websites, these customer segments can calculate the ROI and cost 
savings achieved with the use of their applications (www.xr.health). 
The company’s applications can be used in a clinical environment as well as at home. 
Nevertheless, the most important customer segment is the clinics and hospitals which 
then recommend the use of applications for the end-users – the patients. These patients 
are individuals that have challenges with motor, cognitive, physical, psychological, and 
postural ability as well as pain management. Because the solution is registered as medical 
application, the clinicians are usually the ones monitoring and analysing the patient’s 
progress and guide them through the treatment. Alternatively, third party developed 
wellness applications are targeted to any individuals that are interested in exercising at 
home or meditating. The wellness applications are included in the platform but need to 
be purchased separately and directly from the third parties. Third customer segment 
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identified is the pharmaceutical companies that can use the information provided by the 
Data Portal in clinical trials and have substantial cost reductions (www.xr.health). 
Through the External Control, the health care professional can access the analysed health 
data of the patient in order to personalize the treatment according to their needs and level 
as well as follow the treatment in real time. Furthermore, the patient can himself choose 
the game that fits his needs, and by such alter the features of the platform. The XRHealth’s 
interface is user-friendly and thus, easy to use by not only the patient but also the health 
care professional. The interaction is maintained via customers’ own sites in their 
webpages in the section of “Login”. The company provides its contact information on the 
website for personal assistance. Yet, the set-up process is a self-service with detailed 
instructions and setup tutorial in the Data Portal. The interface is well-designed, and the 
aesthetics are considered in order to be more user-friendly. Moreover, the Data Portal can 
be customized for providing the needed information (www.xr.health). 
The service platform’s architecture is a web-based data portal with open API for partners 
to develop their own applications. However, VR headset is needed for the access of the 
applications, whereas the service platform supports different operating systems. 
XRHealth’s applications are distributed through their websites where the interested 
customer can receive a quote from the desired subscription package. The software cannot 
be directly downloaded from the website, but it is assumingly delivered for the customer 
once the payment has been done. In addition, the platforms are supposedly distributed 
through partners such as the third-party developers, clinics and hospitals which 
recommend the solution for their customers. The access for the platform is granted only 
by the subscribers, but it can be used with the users’ own devices (www.xr.health). 
Problem-solving is one of the key activities of XRHealth since they are developing new 
solutions for individual’s problems. Also, platform being their key product, platform 
management and maintenance can be considered as their key activities. Platform 
promotion and networking with partners are required for creating new customer 
relationships.  One of the XRHealth’s key partnerships are the clinics and hospitals which 
promote the platform for the patients. In addition, the third-party developers create 
content into the platform making them an important partner for the company as well. The 
partnership with the VR headset company Oculus benefits both companies since the 
platform is compatible with only their VR headsets. Moreover, the clinical trials 
J. Vilponen: Digital Therapeutics Solution and Business Model Creation 
56 
 
conducted in hospitals or by pharmaceutical companies provide essential research 
material and clinical evidence about their platform which helps them in further 
development (www.xr.health). 
In a knowledge-based industry, XRHealth’s key resources are the human resources. The 
development of medical applications requires considerable amount of expertise from 
different fields. As a medical device company, evidence is needed from clinical trials to 
support the effectiveness of the solution. Thus, financial resources are essential for 
development of applications (www.xr.health). 
XRHealth generates the revenue by offering its platforms in three types of solution 
packages with a monthly subscription fee: Essentials, Business, and Premium. Each of 
the packages include the Data Portal, VRHealth applications and the External Control. 
However, the packages vary in the amount of sessions and telehealth patients from limited 
amount (Essentials, Business) to unlimited (Premium). In addition, the Premium package 
includes a dedicated account manager and onsite training. The applications of third-party 
developers are not included in the packages and are available for an additional fee 
determined by the partner. The applications can only be used with specific set of VR 
headsets which can be bought from the websites or directly from the manufacturer. There 
are no price data available for the packages which indicates that the prices are negotiated 
between the companies. If the VR headsets are bought from XRHealth’s websites, they 
offer a package solution for that as well which might suggest for bundled pricing 
mechanism. However, the list pricing is used in the manufacturer’s own website for the 
same VR headsets (www.xr.health). 
XRHealth’s cost structure is more a value driven rather than cost driven because they aim 
at delivering personalized solutions for their customers. The company’s costs contain 
people and R&D related activities. Their cost advantage is the economies of scope 
because the company can use their platform in delivering several applications for different 
purposes (www.xr.health). 
6.1.3 MindMaze 
The VISOR framework is used for presenting the business model of MindMaze (see 
Appendix 5). The value proposition of MindMaze is the continuum of care which means 
that the products are developed for several intensities of care depending on the patients’ 
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progress and needs. The products are calibrated before each session to recognize the 
user’s movements and thus, personalize the care for patient’s needs and level of activity. 
Based on evidence from clinical trials, the early involvement results in more effective 
care. Furthermore, a comprehensive management of care, with the help of MindMotion, 
can reduce costs for the clinics (www.mindmaze.com). 
The most important customer segment of MindMaze are the clinics, rehabilitation centres 
and hospitals. The MindMotion solutions both require the involvement of a therapist or 
other trained healthcare professional although MindMotion GO can also be used in home 
environment and requires minimum supervision of a healthcare professional. The end-
users of the product are patients that have experienced a stroke or have other neurological 
conditions such as Parkinson’s, traumatic brain injury, multiple sclerosis, or cerebral 
palsy (www.mindmaze.com). 
In the conventional therapies, the engagement of patients that have suffered a stroke can 
be difficult and early involvement can be hard. The gamified activities engage the patients 
in rehabilitation which can enhance the pace and intensity of rehabilitation. When patients 
are engaged in the activities, they are more willing to do the exercises more often and for 
longer periods. The different games for differing needs enable the treatment to be 
modified for the patient. In the MindMaze’s website, the interface supports interaction 
with a customer support section which is a fillable form that can be sent to the company. 
Furthermore, people who are interested in the company’s activities, can subscribe to their 
email list. Additionally, they provide the contact information of each office on the 
website. The games are user-friendly, and the aesthetics have been considered in the 
design. The personalization of treatment is achieved through the user-calibrated games 
(www.mindmaze.com). 
The service platform’s architecture is based on propriety hardware and software but is 
supported by different operating systems. The awareness of the products is raised in the 
MindMotion’s websites where the customers can find extensive product information. 
However, information about purchasing the products does not exist and, instead, the 
interested customer can contact the company to receive more information. Hence, the 
main distribution channel of the products is their websites. In addition, MindMaze’s 
partners act as the distributors of the solutions for the end-users as well as promoters of 
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the products for other potential partners and customers. The platform can only be accessed 
by subscription (www.mindmaze.com). 
The mission of MindMaze is to solve complicated problems with the help of neuroscience 
and technology. Hence, the company’s key activities include problem-solving through 
the data generated by the platform, clinical trials, and research and development. As a 
software company, key activities include platform management as well as networking 
with partners.  The key partners of MindMaze are the rehabilitation centres because they 
are the ones delivering the solution for the patients. The partnerships with other 
companies have opened new customer segments and opportunities for MindMaze. The 
companies have developed together new solutions for customers as well as benefitted 
financially from each other (www.mindmaze.com). 
MindMaze is in the knowledge-based industry and thus, its key resources are the human 
resources. They have stated that experts from various fields are involved in the 
development of the devices and platform. Because the products do not only consist of the 
platform but also the physical device, they must have physical resources such as 
manufacturing facilities, machines, and distribution systems. In addition, they need to 
provide evidence for the functionality of the solutions which means that many clinical 
trials are conducted that require financial resources (www.mindmaze.com). 
MindMaze does not reveal any information about their revenue streams from the 
products. However, in an interview the CEO of MindMaze has mentioned that their 
products are affordable for individual patients and implies to a $20 - $50 per month fee 
(Knowles, 2019). Based on this, it can be assumed that they receive subscription fee for 
the use of their platform. In addition, the devices generate revenue either by the means of 
asset sale or possibly through renting or leasing the device for the customers. The pricing 
mechanisms assumingly are based on negotiations and the price is customer segment 
dependent. MindMaze’s cost structure focuses largely on the value and delivering that for 
the customers through personalized care. Their costs include the people and R&D related 
activities. As with other companies, the benefit of the platform is that it is suitable for 
delivering various exercises for different needs (www.mindmaze.com). 
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6.1.4 SilverCloud Health 
SilverCloud Health’s business model is illustrated in the Appendix 6 by using the VISOR 
framework. SilverCloud Health’s value proposition is the possibility for scalability of the 
solution according to each organization’s mental health care needs. Moreover, the 
platform provides cost reductions for the customer organizations through patients’ 
improved outcomes and digitality. The clinical engagement, outcomes, and patient 
satisfaction can be measured through data analytics and reporting tools. The platform 
enables more effective health care by reducing waiting time as well as providing easier 
accessibility. Over 15 years of clinical research supports the evidence-based solution and 
development. Gamification of the activities engages the patients into the treatment and 
some of the activities can only be accessed after certain progress has been made 
(www.silvercloudhealth.com). 
SilverCloud Health’s solution is targeted for organizations that can further offer it to end-
users with mental health issues. Thus, their most important customer segments are clinics 
and hospitals. Furthermore, their customer segment includes insurance companies that 
provide the solution for their subscribers as well as other companies offering the solution 
for their employees to increase their well-being. Additionally, the company’s customer 
segment is universities which students can use the services offered by the solution 
(www.silvercloudhealth.com). 
SilverCloud Health’s platform can be accessed conveniently and used at home on the 
patient’s own time. The 8-week program has been divided in a way that the patient is 
recommended to complete one activity per week but according to their own time. 
Moreover, compared to more conventional therapy, the accessibility barriers, such as 
stigma for mental health issues, time availability, and transportation, do not exist. Each 
patient is assigned a supported and the programs are developed for their specific needs. 
The supported provides guidance, encouragement, and other support when needed and 
they are promised to contact the patient every two weeks. Based on the conversations 
between the supporter and patient, the activities are further amended and personalized for 
patient’s needs (www.silvercloudhealth.com). 
The interface provides a possibility for interaction between the supporter and the patient 
through the chat function. In addition, the patient can contact the staff via phone in urgent 
cases. Most of the activities can be used at any time such as a journal provided for personal 
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use. The exercises are interactive which enhances the user’s engagement and learning of 
provided educational content. Furthermore, the company uses social media platforms to 
interact with its customers as well as provides its contact details for further information 
(www.silvercloudhealth.com). 
The user-friendliness and aesthetics are considered highly in the interface. The content of 
the platform can be customized but mainly in the initial stages by a request arising from 
the customer organization. The customer can opt in a self-directed care or a coached care 
whereas some of the tools can be added. The service platform supports different operating 
systems and is based on an open API with a single sign-on and thus, the integration to 
other systems is straightforward. Nevertheless, the platform can be accessed through a 
member or patient portal as well as the website. The partner organizations deliver the 
solution through their own platforms which they are able to receive access by contacting 
the company via their website. The access is granted for individuals that are customers of 
SilverCloud Health’s customers, for example students, employees, insurance subscribers 
and patients. However, the SilverCloud Health’s customers need to acquire a subscription 
for the platform in order to receive the access (www.silvercloudhealth.com). 
In order for the company to deliver the solution for their customer, the platform needs to 
be maintained and developed continuously. Furthermore, their key activities include 
networking with partners for the purpose of gathering additional capabilities as well as 
new customer segments. The patients’ problems are solved by conducting clinical trials 
and through feedback received from the platform. Company’s key partnerships include 
clinics and hospitals that support the clinical trials and deliver the solution for the end-
users. Additionally, the partnerships with insurance companies enables the provision of 
care for the subscribers of the insurance. Universities are helping the company in clinical 
trials as well as delivering care for the students. Moreover, the aim of partnering with 
pharmaceutical companies is to foster the compliance between selfcare and medication 
(www.silvercloudhealth.com). 
In a knowledge-based industry, clinical trials that provide scientific data require human 
resources. Nevertheless, the financial resources are needed for conducting the clinical 
trials and developing the products further. The pricing mechanism of SilverCloud Health 
is based on a fixed annual price which allows the customer an unlimited access to all the 
activities, services (e.g. maintenance, support, etc.), and future activities. However, the 
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website offers limited amount of information about pricing mechanisms and the potential 
customer needs to contact the company for receiving more information 
(www.silvercloudhealth.com). 
The cost structure is based on the value rather than cost, because they focus on 
customizing the solution according to each organization’s needs. The costs, however, 
include maintenance and research and development related activities that arise from the 
conducted clinical trials. Furthermore, the human resources create costs whereas the 
economies of scope offer benefits for the company because the platform can be used for 
offering various solutions and differing activities (www.silvercloudhealth.com). 
6.1.5 Happify 
Happify’s business model is illustrated in the Appendix 7 through the VISOR framework. 
Happify’s value proposition focuses on patient engagement through gamified and 
evidence-based activities. Their platform provides scientific support for different 
activities through educational material, that the user can choose to access before each 
activity. Moreover, the platform emphasizes and encourages the social connection with 
others in the same situation for receiving additional support. For this purpose, they have 
integrated a Community section where the members can discuss, encourage, and support 
one another. The platform can also help in reducing costs when the medical and 
behavioural health care is combined. Furthermore, the platform is offered in 8 different 
languages and is also modified for local cultural needs of the company (my.happify.com). 
The customer segments of Happify have been divided into B2C and B2B customers. On 
the one hand, any individual that wants to feel happy, is a targeted B2C customer segment. 
On the other hand, the platform is mainly targeted for individuals that have the need for 
maintaining wellness of mental health through everyday life or chronic diseases. The 
platform also offers support for diagnosable mental health conditions. Pharmaceutical 
companies are one of the B2B customer segments because the platform has the potential 
for use alongside other pharmaceutical products. Moreover, insurance companies and 
other organizations are considered as Happify’s customer segments because they provide 
the platform for their customers to maintain and develop their wellbeing 
(my.happify.com). 
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In contrast to traditional treatment of mental health, Happify’s platform allows the access 
for the treatment at the patient’s own home at their own time. This is a more convenient 
way for the patient not only because of the easiness of accessing the treatment but also, 
the patient does not have to worry about a certain stigma that might still affect the patients 
suffering from mental health issues. Moreover, the platform provides real-time data and 
reports of patients’ progress for the organizations which allows them to monitor the 
results. The assessment tools personalize the programs for individual’s needs from the 
moment the platform is initialized. Furthermore, the user can choose from the different 
suggested programs which one is suitable for their needs at that moment 
(my.happify.com). 
The Happify’s interface allows the interaction with other members in the community to 
receive support. Then again, Happify interacts with its customers through social media 
platforms and customer support is offered via email. The platform is easy to use, and 
navigation is clear. The aesthetics of the interface have been considered and the customer 
can choose a game he sees fit, which provides flexibility and personalization of the 
interface. However, no other features of interface customization can be recognized 
(my.happify.com). 
Happify’s service platform is based on an open API architecture. Through this, the 
partnering companies can integrate the platform into their own platforms easily. The 
service platform supports various operating systems and can be accessed by the user’s 
own device. The solution is distributed through both application stores, i.e. Google’s Play 
Store or Apple’s App Store, depending on the operating system on the patient’s device. 
In addition, their website is used as a sales channel for the business customers. These 
customers can contact the sales representatives in order to receive more information about 
the solutions offered for companies (my.happify.com). 
Happify has signed an accessibility agreement and, in fact, the platform can be accessed 
in eight different languages. Furthermore, they have taken into consideration the 
accessibility of visually impaired people. The platform has a freemium pricing strategy 
and the platform’s activities can be accessed for free, but the premium activities are only 
available for the subscribers. As merely a software company, Happify’s main activities 
include platform management. In order to deliver the solution for the customers, the 
company needs to maintain, develop, and manage the platform. Moreover, networking 
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with partners is essential for them for reaching new customer segments. The company 
also conducts research in order to solve the arising problems and to develop the products 
further (my.happify.com). 
Happify’s main partnerships include clinics and hospitals that help in delivering the 
solution for the end-users. Furthermore, the partnerships with pharmaceutical companies 
and clinical trial research enable reaching the end-users (my.happify.com). Recently, the 
company has partnered with a pharmaceutical company that supports in the process of 
FDA clearance and reaching new market segments. Additionally, the partnerships with 
other companies as well as insurance companies creates a channel for delivering the 
solution for the insurance subscribers and employees (O'Brien, 2019). 
In a knowledge-based industry the human resources can be considered as important for 
developing the platform and also for delivering the evidence-based results to support that 
research. Furthermore, the financial resources are essential for conducting clinical trials. 
Happify offers its solution for free to some extent and a subscription fee needs to be paid 
in order to access all the features. The subscription fee is 15,99€ per month or 144,99€ 
per year. Additionally, a lifetime subscription is mentioned but the price is not visible. 
Moreover, the company offers a guarantee of 30 days for their services. For B2B, the 
price is presumably negotiated according to the customer segment (my.happify.com). 
As the other case companies, Happify also follows a more value-driven cost structure by 
offering personalized solutions for the customers. The costs consist of people as well as 
the research and development related activities. The company’s platform includes over 
3000 activities and they are continuously developing more of them. Thus, they benefit 
from economies of scope as they are able to use the same platform for delivering a 
growing number of products (my.happify.com). 
6.2 In-depth Interviews 
The demographics of the respondents in the interview are illustrated in the Figure 7. The 
total number of the respondents was twelve. Two of the respondents are outside of the 
client company, whereas the ten remaining respondents are employees of the client 
company. The two respondents from outside the client company act as providing insights 
that are not limited on the client company’s culture that might potentially appear on the 
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responses provided by the employees of the client company. The majority, i.e. six, of the 
respondents are located in Finland, three respondents are in the UK, one respondent in 
France, one in Germany and one in the USA. A more detailed description of the 
respondents can be found in the Appendix 8. 
6.2.1 Value Proposition 
Four of the respondents separately stated that the digital solution would be accepted by 
the customers, whereas non-medical and engagement were mentioned by most of the 
respondents as important factors that can enhance the acceptance of the patients towards 
the solution. Other compelling factors that were mentioned were effectiveness, novelty, 
and monitoring. Furthermore, other factors such as added value and increase of self-
management were mentioned by the respondents. The factors that were perceived as 
compelling characteristics of the value proposition, are illustrated in the Figure 8.  
Figure 8 Compelling Factors 
Figure 7 Interview Demographics 
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Non-medical aspect of the digital solution was perceived as positive by almost half of the 
respondents. People with back pain usually consume a considerable amount of medication 
that impose the patient to side effects. The digital solution, on the contrary, lacks such 
side effects which was perceived as a value-adding factor and increasing the acceptance 
level. One of the respondents considered that an existing opioid crisis could enhance the 
acceptance level of the digital solution for treating pain in the USA.  
“I think there's quite a big opportunity in the US market to, especially around 
communications, bringing this as an alternative […] to the opioid issue, right. […] 
non-drug approach to alleviate pain and support patients that quite frankly may be 
concerned even to start taking painkillers because of everything that's happened.” —
Respondent 6, USA  
However, it was emphasized that research data needs to support the lack of side effects. 
By the support of clinical evidence, the digital solution may be perceived as an alternative 
to a more conventional type of treatment. 
The engagement to the treatment was perceived as providing value for the customer 
through the digital solution. The gamification of the treatment makes the treatment 
entertaining and fun which results in higher motivation among patients to return to the 
therapy. Furthermore, the gamification was perceived to encourage the patients for 
movement through the various challenges and immersion of the VR environment. In 
addition, when patients feel that their needs have been acknowledged, for example, by 
asking some initial questions, the engagement is enhanced.  
“But even if you added in the software [a] section at the beginning, that ask the patient 
[…] to describe the type of issue they're trying to deal with, and […] what kind of 
movement gives them the most trouble […] then, even just saying ‘Okay, we're going 
to be showing you a program that we think will be right for you’. Now, if that program 
is exactly the same, regardless what the answers are, most people will feel more 
satisfied with it regardless, because they felt they've been heard before they take 
something. “—Respondent 6, USA 
Even though the older generation’s acceptance towards the digital solution was perceived 
as a challenge by some of the respondents, the results from the conducted feasibility 
studies have argued otherwise. One of the respondents working closely with the project 
stated that there has not been any less interest among the older generation. The possibility 
for monitoring patients’ progress was perceived as a value creating factor. The existence 
of monitoring tool was even perceived as enhancing the patients’ quality of life. 
J. Vilponen: Digital Therapeutics Solution and Business Model Creation 
66 
 
According to the respondent, the medical professionals would be interested in receiving 
the generated health data, whereas the patient could see real-time results of the treatment.  
The digital solution was perceived as offering a novelty treatment and new experiences 
for various generations. For example, the clean and white hospital environment could be 
experienced as more interesting, comfortable, and enjoyable by creating a new 
environment with the digital solution. Especially, among the younger generation, that is 
accustomed to use such digital platforms, the interest and acceptance could be high as 
well as engaging. In fact, it was perceived that this type of solutions would generalize 
increasingly as the younger population grows older. One of the respondents realized a 
clear need for treating pain with a digital therapeutics solution.    
“And there are lots of people who face some kind of pain, and even really nasty pain, that 
is disturbing their daily life. So, there is really real need for this type of solutions.” —
Respondent 2, Finland 
The digital solution was perceived as a cost-effective approach for clinics and hospitals 
to treat low back pain patients. In addition, the insurance companies were considered as 
interested in providing such treatment that costs less than standard therapy, but is at least 
as effective, or even better. Furthermore, the digital solution was perceived as an effective 
treatment that reduces pain and, for example, prevents absenteeism at work.  
The respondents perceived that the acceptance of the solution would be high, because it 
creates additional value for the customer. Furthermore, the increasing willingness for self-
management increases the level of acceptance among the customers. However, the cost 
of the device or lack of the payer was seen as a barrier that needs to be undertaken.  
“But I guess […] patients would use the solution, especially if they do not have to pay for 
the solution.” —Respondent 4, Germany 
Even though the likelihood of acceptance would be high, one of the respondents 
emphasizes that before deciding, the users need to see the digital solution. Another 
respondent adds that the solution and marketing must be based on medical device while 
many of the respondents highlighted that in order for consumers to be certain about the 
solution’s functionality, it needs to be recommended by medical professionals.  
Most of the respondents perceived the individual consumers as a viable option for target 
group. The division of the considered target groups are illustrated in Figure 9. 
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Nevertheless, the majority of these respondents argued that the individual consumers 
should not be focused first whereas the digital solution should be recommended by the 
medical professionals. 
“— maybe in later stages when this is already shown to medical professionals and to the 
greater audience that this is a very good solution for pain management, […] I would 
say that then to concentrate to individual consumers more, but I would start with the 
organizations.” — Respondent 1, Finland 
In many cases, the pain patients are individuals that stay at home and are familiar in using 
actively digital tools, such as smart phone and tablet. Thus, the digital solution was 
perceived as a natural way of treating pain for these people. However, the respondent 
stressed that it is vital to build a credible brand which could be achieved by carefully 
selecting partners. Moreover, some of the respondents emphasized that the digital 
solution might merely be purchased by the patients that have already tried everything. In 
the UK, it was perceived feasible to start with the individual consumers that would 
purchase the digital solution from the pharmacies as an over the counter product. 
However, the respondent addressed concerns related to the price as well as proven 
medical data.   
 “I mean, unless they are really, really, suffering and have huge burdens on their quality 
of life, and they're so desperate to try […] and also the price point of this treatment is 
something that they feel it's [sic] acceptable.” — Respondent 3, The UK  
On the contrary, the French respondent perceived that the payers would not necessarily 
be ready to pay for such a solution as an out-of-the-pocket payment in France. 
Furthermore, in case the individual consumers are focused on first, the digital solution 
cannot be marketed with clinical evidence supporting the claim and thus, prescribed by 
Figure 9 Division of Considered Target Groups 
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the doctors. Thus, the target group of individual consumers can be used for collecting data 
and proving the digital solution’s feasibility. The importance of affordability and 
simplicity for awareness building and allowing a widespread among the individual 
consumers were agreed by the majority of the respondents.  
“It depends on the final solution. If we have a simple version which works already, but 
with which we want to collect more clinical evidence for, e.g. regulators and payers 
we might want to start with B2C.” —Respondent 1, Finland 
“—if it's not hugely expensive and we can […] provide it relatively cheap to wide 
audience, then you should go to the individual consumers, because then you get the 
widespread” —Respondent 8, Finland 
The division of organizations considered as important stakeholders by the respondents 
are illustrated in Figure 10. The organizations were perceived as an essential link in 
delivering the solution for the end-users by most of the respondents. Additionally, it was 
agreed that the health care professionals are the ones instructing the patients for correct 
use of the solution.  
 “The first thing is you need the support of people who are important in the management 
of the disease. So, B2B first is critical for sure, because […] your software will have 
a value and […] the value of your software and program will be spread by the experts 
[…] of the disease […], but this has a value that should be explained or […] spread 
to the patient thanks to the expert in that. So, the credibility of your platform will 
come from them.” —Respondent 5, France 
Almost each respondent mentioned the importance of patient organizations in delivering 
the solution.  
Figure 10 Division of Organizations 
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“I would focus here on those associations which are working on opportunities to solve 
[…] those problems. Since we are talking here about a kind of therapy, so, you should 
work together with associations which are focusing on therapy opportunities, options, 
alternatives, and those would be, for example, more important.” —Respondent 4, 
Germany 
Hospitals were also considered as one of the most valuable stakeholders by almost each 
respondent. It was perceived as an important delivery channel in terms of building 
credibility and awareness among the patients. In addition, hospital is a place from where 
the pain patients naturally seek for help, which makes it an obvious target group. Few of 
the respondents pointed out, that doctor’s advice is highly appreciated - especially in 
Europe. Hence, the health care professionals in hospitals should be convinced by the 
solution for them to recommend it to the patients.  
“— you need to have the support of the physician. […] probably all over Europe, if the 
physician said you should have that, you should use that, because it will be good for 
you, for your wife or—then the patient would use that.” —Respondent 5, France 
“— even the nurses could recommend this or so. So, I think at that point, especially in 
Finland where the patients are really following the orders of doctors quite well, I think 
it could start, if the cost of this equipment is not too high or it would be compensated 
somehow.” —Respondent 2, Finland 
Half of the respondents mentioned various clinics, and most importantly the ones 
concentrating in pain, as vital stakeholders that could offer the digital solution for pain 
management as either an additional or alternative treatment. The trials conducted in these 
clinics, and samples of the solution in some form were perceived as viable ways to deliver 
and build awareness of the digital solution.  
 “I think it should be in the clinics where [this] type of patients would naturally go first. 
So, I would target the clinics where are people suffering from the pain and where are 
the neurologist, orthopaedist, GPs, nurses, certain physiatrists even. I think that, that 
would be the start.” —Respondent 2, Finland 
Private insurance companies were perceived as an important target group because of their 
potential interest towards a cost-effective digital solution included in the health 
insurances. This is the case especially in countries like Germany and USA where the 
private health insurances are popular among the population.  
“— do not forget here to involve in […] quite early stage health insurances. Since at the 
end, it's necessary to get this solution also paid and here, especially in Germany, health 
insurances are important.” —Respondent 4, Germany 
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“— in countries where you have insurance companies like Germany, for instance, then I 
would certainly go and trying to target them, because really […] if they have to pay 
out for people who have lost salaries and they have to compensate them because of 
back pain, then they probably will be more willing to look at paying for these kind of 
things, so that they can save on the other side.” —Respondent 3, The UK 
“US consumers are much more used to paying for things out of pocket, rather than hoping 
you will be covered by like a national insurance program which doesn't exist in the 
US, so private insurance.” —Respondent 6, USA 
Especially in the US markets, the importance of corporate welfare was emphasized by 
one of the respondents. There is a vast potential in the private organizations to deliver the 
digital solution in their health care package. The number of low back pain patients in 
companies is high whereas in a large company’s scale, even a small percentage of people 
suffering from back pain, would imply hundreds of patients in one single company. 
“So, I actually, of all the targets, I would really go after those first, more than anyone else 
because they have a direct savings and major interest in making sure that some of the 
missed workdays can be avoided. There's a real tangible financial benefit to these 
companies to where they might sponsor this internally. So actually, corporate welfare 
programs will be at the top of my list for this type of product.” —Respondent 6, USA 
Other stakeholder groups that were mentioned by the respondents were professional 
societies and charities, pharmacists, and e-health providers. In addition, reimbursement 
organizations were mentioned, in case there is willingness for seeking reimbursement. 
Furthermore, one of the respondents emphasized the importance of technically oriented 
company that could provide assistance in building the road and granting access for a 
potential customer base.  
When the digital solution was compared to a more conventional type of treatment, various 
factors were mentioned regarding the complementary aspects of the digital solution (see 
Figure 11). One of the benefits perceived by almost half of the respondents was the 
accessibility. The limited number of health care professionals and barriers regarding 
available time and financial resources were recognized as non-existence in the digital 
solution because it can be used at home. Furthermore, the type of treatment does not 
necessarily change, but the value is carried through this different type of accessibility and 
providing a different scenario for the patients.  
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Almost half of the respondents perceived that the digital solution was approaching the 
chronic low back pain from a different angle and providing a new way of treating pain. 
The patient is taken into a different world which allows him to learn new things and 
possibly even forget the pain. 
“Create a virtual world which cannot be created in the psychologist’s office” —
Respondent 11, The UK 
“I would see that this would have a greater impact to their quality of life, for these persons, 
than the conventional treatment.” —Respondent 1, Finland 
Some of the respondents also emphasized, that the digital solution is not necessarily the 
only therapy, but rather an alternative, or an add-on therapy – a complement to medicine. 
One of the respondents mentioned the barriers regarding psychological issues and a 
certain stigma associated with mental health whereas the digital solution might lower this 
type of barrier for the patients seeking for treatment.  
“— everything is basically nowadays connected, even the patients, which are […] 
working with the mobile phones and smart devices everyday basis, and this […], in 
my opinion, lowers the bar to seek help for certain issues, especially with people who 
have psychological issues and sort of feeling shame. And in chronic pain, there's some 
elements involved in that.” —Respondent 7, Finland 
The co-creatibility and personalization of the treatment according to the patient’s needs 
were seen as important by all the respondents. The personalization was perceived to create 
value for the customer through factors illustrated in Figure 12.  
Figure 11 Complementary Factors 
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Few of the respondents perceived the personalization as important but not in the first 
release whereas the personalization could be included in the later releases as an enhancing 
factor. The possibility for personalization of treatment according to patient’s needs is 
identified as highly important by almost each respondent due to individual patients’ 
differing levels, limitations, and expectations towards the treatment as well as different 
demographic groups’ (e.g. gender, age and tech-savviness) requirements. Moreover, 
through personalization, the patient is able to feel that the treatment is addressed to him 
and not generalized to anyone’s needs. This increases the patient’s engagement into the 
treatment. In contrast, one of the respondents would only perceive personalization as 
important if the patient would have phobias that need to be taken into consideration. 
One of the respondents proposed that the personalization should be based on person’s 
needs examined by questions regarding the patient’s condition. Then, the activities could 
be adjusted according to different types of patients, or conditions.  
“So, I think it's important for any of these packages to have some way to first classify the 
patient or what things they might be having […] smaller pain or more difficulty with, 
and then fine tune its recommendations accordingly. So, if it's a doctor that visits the 
patient, and then he's able to send to the software, some things saying […] ‘lifting 
with the right arm is very difficult, so less do the lower stress type of movement with 
that.’ Then this, I think, would be helpful, but to just have a generic one size fits all 
approach, in this case may and may not get the results that we want, perhaps may even 
tell people that, this thing doesn't understand that, that hurts.” —Respondent 6, USA 
The possibility for personalizing the treatment was perceived as an engaging factor that 
allows the patient to tailor the experience according to their own needs. This, in fact, 
increases the attractiveness of the solution itself.  
Figure 12 Factors of Co-Creatibility 
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“— personalization is more to do with trying to enhance patient compliance, so that 
patient will not abandon this.” —Respondent 3, The UK 
One of the respondents emphasized the importance of making the platform interactive so 
that medical professional are able to see the patient’s progress and, when certain steps 
have been achieved, the patient is given the possibility to choose the additional features 
included into the platform. Two of the respondents emphasize the importance of offering 
a variety of different activities. A suggestion for further patient engagement could be 
achieved by providing different scenarios every day. This type of element of surprise 
could make the patients return to perform the activities day after day. Also, one of the 
respondents proposed that different elements from other applications, such as Spotify, 
could be combined with the platform.  
“— music would be extremely important for elements like this because music has been 
proven […] to decrease pain, for example, in a very efficient way. […] you're doing 
certain kind of movements, but how do you do the movement - is there […] terrible 
elevator music, or can you choose your own favourite […] list.” —Respondent 7, 
Finland 
For the purpose of personalize the treatment, the gathered health data is assessed, and the 
treatment is amended according to the patient’s needs. The personalization, then, can be 
done based on medical professional’s assessment, or technology’s assessment (e.g. AI 
changing the difficulty level according to patient’s progress) of that data. Furthermore, 
the patient can choose the activity based on his perception of needed treatment or the 
personalization can be based on a combination of these three aspects. The division of 
perceived factors affecting the personalization is illustrated in Figure 13. 
Figure 13 Personalization Based on Health Data Assessment 
J. Vilponen: Digital Therapeutics Solution and Business Model Creation 
74 
 
More than a half of the respondents perceived as the most feasible option a combination 
of the assessment possibilities. Even though the medical professional’s assessment is 
important for delivering safe treatment for the patient, solution needs to still answer each 
stakeholder’s need. One of the respondents perceives technology’s assessment as the most 
beneficial one because it releases the patient or medical professional from manual work. 
In contrast, another respondent concludes that patient’s assessment would enhance his 
compliance to solution while his motivation increases through the visibility of data, and 
accomplished progress. Furthermore, the possibility for patient to choose the intensity 
level of the activity was perceived as important.  
One of the respondents stated that the patient must have the control over the process, but 
the medical professional can have the responsibility for setting the parameters. In fact, 
the medical professional’s assessment was perceived as vital by many of the respondents, 
because the treatment is eventually based on medical data. Likewise, the digital 
therapeutic may pose a risk to the patient and make the pain worse, if the activities are 
done incorrectly. Some of the respondents perceived the human interaction important and 
recommended the medical professional’s assessment included too. Furthermore, an 
encouragement from a medical professional can increase the patient’s willingness to 
finish an activity or choose a higher intensity level exercise.  
One of the respondents highlighted that the AI driven assessment cannot be in the first 
versions of the digital solution, due to the lack of gathered data. However, it was 
perceived that the AI can enhance the effectiveness of the solution as well as develop 
recommendations for the patients based on initial questions. Moreover, the AI can 
increase the patient compliance and engagement by following the patient’s activity level 
and sending reminders based on the assessment.  
6.2.2 Interface 
The factors affecting the functionality of the interface are depicted in Figure 14. Almost 
each of the respondent perceived the interface’s user-friendliness as a vital factor of the 
digital solution.  
“User-friendliness is everything.” —Respondent 7, Finland 
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“It has to be user friendly. Otherwise, I don't think it will work out. I think this is a must, 
must. And of course, that it's so easy to train and user friendly so that people are really 
doing the exercises what is needed and there are no […] excuses or anything like that 
they would drop out. Yeah, so I think this is really crucial. […] I would say, to get 
[…] high acceptance, user friendliness would be most important” —Respondent 2, 
Finland 
“I think it's very important actually, that the solution is user friendly, because I think this 
is the whether it will be used or not. That it's very, very important because then […] 
you get even more anger and you get even more pain if it's not […] you have to 
struggle with the […] solution.” —Respondent 8, Finland 
The respondent perceived the interface as user-friendly when there is no need for large 
manuals, or not a lot of effort is needed in the setup phase and, for example, the elderly 
population would be able to use the solution with ease. It was concluded that if the user-
friendliness is not considered, the solution would not, most probably, be used. One of the 
respondents argued that the user-friendliness needs to be considered from the customers’ 
point of view as well as improved continuously based on the customer feedback.  
The different possibilities for interaction proposed by the respondents are illustrated in 
Figure 15. Data collection was perceived as a useful function that would benefit the 
service provider, patient as well as the medical professional. The collected data could be 
used for monitoring of patient’s progress and also the actual benefits of solution. 
Furthermore, the saved data could be utilized in face-to-face interactions with the patients.  
 “It would be good to have visibility of the data for both the patient and the clinic so that 
they can follow the progress and e.g. before next clinic visit the HCPs [Health Care 
Professionals] would already know a lot of the basic data and could focus on the F2F 
discussion with the patient.” —Respondent 9, Finland 
Figure 14 Functionality Factors 
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The respondents perceived a possibility for interaction with a medical professional as 
important. A contact point with medical professional would allow the patients to share 
their progress or ask for help in case of facing problems. In addition, one of the 
respondents proposed a possibility for Skype call with a friend during an exercise or 
sharing an accomplishment in social media. Moreover, the respondent emphasized the 
importance of interaction with a community of people suffering from a similar condition 
whereas another respondent proposed a possibility for multiplayer or group therapy.  
Reminders and questions about patient’s condition were perceived as a factor that creates 
an emotional bond between the interface and the patient. Moreover, the possibility for 
purchasing add-ons as well as giving customer feedback were proposed for possibilities 
of interaction. In comparison, it was perceived as important that the interface gives 
feedback to its user as well - either as sound or physically. For example, the haptic motors 
in the handsets would indicate the user that the movement is done correctly.  
“Even if people might be moving things the wrong way, something that just by the way 
the device’s shaking or clicking indicates to them ‘Yes, it's the correct motion’ or ‘No, 
it's not the correct motion’. I think [it] will be important from a design point of view. 
So even more than what you just visually see.” —Respondent 6, USA 
The form factor and fluidity affect the interface’s outlook and design. The division of 
respondents’ perceptions regarding these characteristics are depicted in Figure 16. Half 
of the respondents perceived that the outlook and the aesthetics of the interface design 
should be considered by creating an attractive enough solution for the user. The patient’s 
interest towards the solution is enhanced with a pleasant design. In addition, the cultural 
understanding in the design was perceived as an important aspect by one of the 
respondents and certain colours or words should be taken into consideration, such as the 
Figure 15 Interaction Possibilities 
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colour red in China where it is considered as positive, but that might not be the case in 
every culture.  
“I see yes, it's important. It's the look and feel of the—it's also part of the how much 
customer is going to use it, because if it's hard to use, and if it does not look modern 
and nice environment I see that has an effect to the amount how is it going to be used. 
So, I say it’s very important.” —Respondent 1, Finland 
The majority of the respondent perceived the possibility for customization of the content 
as important. On the one hand, the patient can set the scene, choose the colour of the 
background, or select their own avatar. On the other hand, the possibility for 
customization was perceived as essential for patients that have physical limitations and 
cannot perform certain tasks.  
“I'm doing this like a movement in a meadow somewhere […] in Wales or in a beach in 
Hawaii, so that kind of elements has to be, in my opinion, very carefully tailored in 
the software. The visual elements has to be extremely good, in my opinion, because 
patients who has these sort of elements; seeing […] positive things that they like, and 
hearing things that they like, combining that they are moving, I think they're 
encouraging each other and they all sort of link to each other.” —Respondent 7, 
Finland 
When patients have the opportunity to customize the content according to their own 
hobbies or interest, they are able to feel more relaxed and happier. Consequently, it would 
allow different types of people to commit into the solution.  
“Yeah, yeah, no, I think it's critical, no, really critical. I mean, one thing is customized 
the types of exercise, but the other one is also the scenarios and the games or activities 
need to be entertaining enough and changing enough to keep people engaged.” —
Respondent 6, USA 
Figure 16 Interface Characteristics 
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Nevertheless, few of the respondents perceived the possibility for customization as 
important, but they did not find it necessary for the first launch of the solution. Moreover, 
it was perceived as customer-dependent and the user would be able to choose whether 
they want it or not.  
6.2.3 Service Platform 
The division of respondents’ perceptions about the characteristics of the service platform 
are depicted in Figure 17. The possibility for opening the platform for third parties was 
perceived as a possible or interesting suggestion. The features added by the third-party 
developers were perceived as value-adding factors, such as personalized solutions and 
easiness of use. However, the majority of the respondents were concerned about the 
regulatory and legal aspects regarding an open access platform. Thus, it would be crucial 
that the client company would be in charge of managing added features as well as the 
gathered data. Nevertheless, there was a fear of third-party developers damaging the 
brand image while the opening was not recommended by the respondents.  
“— if it's opened to third parties, yes, that's really nice, if they can provide their added 
features, but it needs to be agreed and transparent. And […] them [client company] 
managing this one and it's their product, then they need to be able to decide what is 
going to be added there. So, if something added, then it needs to be agreed separately.” 
—Respondent 1, Finland 
“The content in our current developed device is carefully design by a trained CBT 
specialist. I would not open it up for anyone to develop further as one then could lose 
the intended benefit” —Respondent 12, Finland 
Even though the architecture was mainly perceived to be maintained as proprietary, some 
collaboration with third parties was considered as beneficial. However, the majority 
Figure 17 Service Platform Characteristics 
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concluded that more knowledge and understanding need to be gathered before the client 
company would be ready for such a solution.  
 “Some kind of collaboration could be beneficial. We could e.g. have different pain 
treatments available via one platform and patients would be allocated to the one that 
is most suitable for them. We could also have some nutrition, physical exercise, music 
therapy etc. available to choose from.” —Respondent 9, Finland 
The possibility for supporting different operating systems was not included in the 
interview questions, but two of the respondents mentioned that it would be important to 
consider different operating systems, especially iOS and Android.  
“Yeah, definitely, because […] the world is basically divided by Android users and iOS 
platform users. […] it's very much depends the VR glasses, which technology they 
are actually functioning. So, it means that having both the iOS environment and 
Android environment is extremely important.” —Respondent 7, Finland 
The respondents mentioned three main delivery channel options for the digital solution 
that are illustrated in Figure 18. More than a half of the respondents considered that the 
digital solution should be offered by different medical professionals, such as hospitals, 
clinics, and doctors.  
“If we can win them, I guess it's easier for them to convince patients. […] they are 
responsible for the success of such a solution and they are the ones which should use 
it regularly, but I guess they need guidance and they should get guidance from their 
medical doctors and I would start here with organizations in kind of hospitals.” —
Respondent 4, Germany 
The education about the solution and introducing it to the patients was perceived as the 
task of the medical professionals. After the patient has tried the solution in a safe 
environment, i.e. hospital, the patient could take the device home and have regular visits 
Figure 18 Points of Acquisition 
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to a rehabilitation centre or clinic. The feasibility of the different delivery channels is 
country specific and, for example, in the UK a credible solution was perceived as selling 
a device, that is downloaded beforehand, over the counter. Some of the respondents 
highlighted the need for various delivery channels for different target groups.  
Few of the respondents considered that the digital solution should be downloadable from 
an application store, Amazon, or client company’s website. In case the solution would be 
offered in a web-based store, the application or pre-configured device should be released 
with a code that is offered by a medical professional. However, in case the solution is 
available for patients’ own device, the client company’s website was perceived as the 
most viable delivery channel. In conclusion, few of the respondents emphasized that more 
research is required before a decision about the delivery channel can be established.  
The majority of the respondents perceived that the accessibility of the digital solution 
should be convenient for the customer.  
“— but the access has to be easy. Like now, I would be just downloading, while we're 
talking, I would download the application into my iOS, and I would start using it. That 
easy it has to be.” —Respondent 7, Finland 
A possibility for trial period was perceived as a feasible option that allows the customer 
to feel and see how the solution looks like. Furthermore, the trial period would enhance 
the adoption and success of the solution as well. Most of the respondents argued that a 
free access could be granted, but not for a long time, for example, an access for a limited 
version and through subscription, the user would be granted an access to more features. 
In addition, this type of preview could also contain information about the decided option 
for acquiring the VR headset.  
“Or I would develop some kind of element that you can preview the software when you 
download, for example, the application in your phone that you can actually use it to a 
certain extent, just by using your mobile phone, for example. So, you can have a trial 
out and then basically it says that, okay, but you need to have VR glasses to complete 
and see all of these elements.” —Respondent 7, Finland 
The challenge with a free access comes to the revenue streams and one of the respondents 
was concerned about the number of advertisements that free applications normally have. 
Conversely, a restricted access would also limit the results for proving the clinical 
effectiveness. Thus, a balance between these two aspects were perceived as important in 
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order to provide a feasible access option for the patients. Furthermore, the possibility for 
trial period was perceived as country-specific and not important in each country.  
“So, I think in the US, it may be easier to have people just buy directly without having 
this access first. I think in a lot of European markets, you may need to have the 
introduction to this device from a doctor or clinic, and then people adopted on their 
own.” —Respondent 6, USA 
6.2.4 Organizing Platform 
The core business processes perceived by the respondents are illustrated in Figure 19. The 
majority of the respondents perceived the sales and marketing as important business 
processes. On the one hand, the decision of delivery channels and the overall distribution 
are part of the core business processes. On the other hand, the marketing activities, such 
as the promotion, branding and awareness building was considered as an essential factor 
in delivering the solution and making it available for the customers. 
One of the respondents emphasized the importance of ensuring that the material about the 
solution is available for the customer. Moreover, the client company needs to carefully 
design the commercialization strategy in order to be successful. Trial period, patients’ 
recommendations and showing the benefits on the internet were perceived as important 
awareness building activities.  
“You have to also see from the patient perspective: the doctor recommends, the patient 
then decides whether he takes it or not. And where the patient looks for the 
confirmation, it is basically, you know, accessing Google and then finding the 
information. And you have to have the story built there, ready for the patient and sort 
of influencing the decision-making process.” —Respondent 7, Finland 
Figure 19 Core Business Processes 
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Ultimately, the patients and potential end-users are in hospitals and clinics. Thus, it was 
perceived as important that the doctors and other medical professionals would be willing 
to recommend the solution for the patients. For this, the medical studies and clinical trials 
are needed in order to gather research evidence to support the digital solution. The 
majority of the respondents recognized the research and development activities as core 
business processes.  
“— the strong data to support the rationale and the emotional part of the solution, I think 
this is the key.” —Respondent 2, Finland 
Half of the respondents raised the concern about the hardware and its potential defects. 
Therefore, a support function was perceived as one of the core business processes 
required for delivering and supporting the value of the digital solution. Furthermore, a 
local support service should exist in case the customer breaks the device. 
“If you're talking to something with a VR device either headset or things like that you 
need the local distributors. You cannot have something only web based because if the 
patient or someone has to pay […] for the device, then you are expecting locally to 
have a support. If it doesn't work or if you fail to connect the device, to the solution 
or whatever problem you could have on a daily basis you should have a local support 
somewhere. It cannot only web based” —Respondent 5, France 
Many of the respondents emphasized that such business process does not exist in the 
client company at the moment but is an essential service that is needed either in-house or, 
alternatively, offered by the VR headset partner company.  
The continuous improvement of the digital solution based on the gathered results and 
customer feedback was perceived as part of the core business processes by the 
respondents. One of the respondents stressed the importance of multifunctional teams that 
should work together in developing the solution. Moreover, the medical professional’s 
feedback was perceived as vital.  
“— then you could ask easily for doctors that how likely it is that you would recommend 
this to patients, and to which type of patients, and how the nurse is feeling then in the 
pain clinic and so on. I think you could do this, type of questions to the customers, 
whether they would recommend this or not. And I think that is something. Maybe 
even patient associations for pain and something that you could approach also and 
asking how do they see that […] So, I think those would be important.” —Respondent 
2, Finland 
The user requirement mapping was perceived as essential by two of the respondents for 
engaging the patient more into the treatment. Furthermore, the gathering of the health 
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data and customer feedback can be initiated by testing the solution with a proportion of 
customers.  
“I think the focus should be really on coming up with the right types of exercises, the 
right type of interaction and visuals that really engage people to keep them using the 
program and actually being able to start collecting some real noticeable health 
results.” —Respondent 6, USA 
One of the respondents considered that the value can be supported through defined 
processes of treatment which are a prerequisite for reimbursement. The respondent 
concluded that activities regarding medical and regulatory aspects need to be considered 
in the initial stages.  
“Maybe you will get a certification, I guess it would be a CE certification for a medical 
product, but you also have to think about, what is really the concept behind and I 
would include here quite fast regulatory experts.” —Respondent 4, Germany 
The life cycle management of a digital solution differs largely from the client company’s 
existing business processes and, according to one of the respondents, should probably be 
separated from other processes.  
 “— typically, our lifecycle management in pharma is still […] we're talking about totally 
different time frames because this production [needs] to be […] all the time also 
improved, and you need […] all these taken into account. How you actually 
commercialize, how you manage it, because this comes— so, that you actually keep 
the competitiveness, I would think. Because otherwise there's another solution and 
you are there for a year and then you are out, or even less if you are kind of un-lucky.” 
— Respondent 8, Finland 
The ecosystem partners perceived as viable for the digital solution by the respondents are 
illustrated in Figure 20. Almost each of the respondent considered a company offering IT 
solutions, IT development service, or a software company as a potential ecosystem 
partner. These companies were perceived as partners that could teach new things and 
offer services regarding such technical expertise that does not exist in the client company. 
Furthermore, consultancy could be acquired from Digital Therapeutics (hereinafter 
referred to DTx) companies for delivering, developing, and building a network for the 
digital solution. The development of digital capability with these companies, was 
considered as essential for success.  
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“— but really get into the DTx experts in terms of—maybe we need to talk to consulting 
firms who have more experience with dealing with this in the major European 
countries for advice because […] we don't have the internal expertise on this I'm afraid 
at the moment.” —Respondent 3, The UK 
“We may need to partner with someone who is already doing this or build this together 
with consultants who have some expertise in the area.” —Respondent 9, Finland 
Moreover, different advisory boards were perceived as an essential partnership for 
providing further technical advice and consultancy in delivering the solution.  
 “And I would definitely not sit here at [client company] but I would go and sit somewhere 
like in Innovation House Finland and […] going sit [with] them in terms of open 
community. Share about this and find people who can actually build awareness of this 
software and get the right people on board because you need like really tech savvy 
people promoting this and developing this.” – Interviewee 7 
The advisory boards should consist of people from different functions as well as different 
areas of the world for gaining thorough understanding about a feasible delivery of the 
solution. These networks could offer the required added-value and knowledge. Patient 
organizations were perceived as important ecosystem partners for building awareness 
among potential customers and further targeting the correct patient groups easily.  
Partnerships with insurance companies would allow digital solution to be offered in the 
health care packages which was perceived as beneficial by one of the respondents. In 
addition, almost half of the respondents perceived the hospitals, clinics, and medical 
professional networks as important ecosystem partners. Through these partnerships the 
solution could be offered for pilot patients as well as clinical evidence could be gathered 
trough trials.  
Figure 20 Partnerships 
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The respondents perceptions about the inner capabilities and resources required to acquire 
outside are depicted in Figure 21. The resources regarding technology, digital content, or 
digital marketing were perceived as capabilities that should be acquired from outside or 
through partnership. However, one of the respondents highlighted the importance of 
understanding the purchased services and products in order to maintain the independency.  
 “—still we need other capabilities because we have to develop the digital capability, 
exactly this kind of understanding of the systems. We cannot even purchase them 
from abroad, if we don't have […] sufficient understanding for all of these […] 
matters, so […] we need to build the capabilities, but not of course everything. It 
doesn't make sense to do everything in house but in order, even, to kind of purchase, 
we need to understand what we purchase because otherwise it's […] totally reliant on 
the external partners and we cannot do the best choices because it depends on what 
we hear.” —Respondent 8, Finland 
The inner capabilities of the client company perceived by the respondents are depicted in 
Figure 22. Some of the respondents perceived that the client company does not have any 
inner capabilities for delivering the solution. 
“— Because this is not a drug, this is not a medicine. It works in a totally different 
environment that [client company] has been working before. It means that we have to 
be making decisions that we haven't usually be making, it has to be— it means that 
we have to be more willing to adapt risk that we've been doing before because we are 
not, you know, any more manufacturing a drug with this.” —Respondent 7, Finland 
“Because we do not have any process for actually […] delivering this because […] if you 
are talking about the device, there are many matters in […] commercialization […] 
that it is currently in— not in a business processes.” —Respondent 8, Finland 
Figure 21 Pooling of Resources 
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Nevertheless, most of the respondents perceived that the client company does have inner 
capabilities that can be leveraged in delivering this digital solution for the customers. One 
of them is the knowledge and the expertise of people.  
 “— inner capabilities, we have so much knowledge in this company. So […] people have 
long, long histories, they have a lot of knowledge. And I think that we should leverage 
that knowledge and from multiple sources and […] from different functions working 
together and thinking, how we can deliver the best solution. That's something I see 
that we are really, really, good at. “—Respondent 1, Finland 
Four of the respondents recognized the sales and marketing as client company’s inner 
capabilities whereas the existing sales force and distribution channels need to be altered 
to some extent for the purposes of the digital solution. One of the respondents concluded 
that the client company is able to conduct clinical trials by themselves.  
6.2.5 Revenue Model 
The different options for pricing the digital solution perceived by the respondents are 
illustrated in Figure 23. The majority of the respondents perceived the subscription-based 
pricing mechanism as the most feasible one due to the engaging and committing effect. 
However, it was highlighted that the unsubscribing should be made effortless for the 
customer when they are not using the solution anymore.     
Figure 22 Inner Capabilities 
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Some of the respondents suggested a fee for the period of treatment and then a 
subscription fee would be charged for additional features and services, such as 
maintenance, follow-up, etc. In addition, one of the respondents proposed an annual fee 
for the first year and if the customer is willing to continue with the program, they would 
need to pay a subscription fee for access a certain number of features in the program.  
“More than a subscription, I think it's a deletion of the payments in some markets where 
instead of having to pay 700 up front, you can pay 29-30 euros per month, over a year. 
This might be a model that lowers the barrier for some people to get access to it.” —
Respondent 6, USA 
For business-to-business (hereinafter referred to B2B) customers, the pricing mechanism 
was perceived to be different. The proposed pricing mechanisms were based on volume 
or license while a payment per active user was also mentioned.   
“For B2B we could have an annual fee covering a certain number of evaluations (i.e. is 
the treatment suitable for the individual), licenses and possible also population data. 
There could also be a separate fee for all three components mentioned. […] Prices 
could be volume-based i.e. if a clinic/insurance company is buying many licenses the 
price might be lower than for single user.” —Respondent 9, Finland 
Some of the respondents perceived the module-based pricing mechanism as a feasible 
option for the digital solution. The access for different modules and features would be 
granted by an additional fee. Only one of the respondents considered the advertising in 
the platform as one of the feasible revenue streams. However, another respondent was 
concerned about an excessive amount of advertising which could result in poor reviews 
by the customers.   
Figure 23 Pricing Options 
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One of the respondents was implicit about receiving a reimbursement for the solution. In 
Germany, this type of model is important due to the compulsory insurance.   
“Get reimbursement. […] Try to get reimbursement. That would be the best model to get 
such a solution accepted. […]—And sold, of course. “—Respondent 4, Germany 
Additionally, two other respondents considered the possibility of reimbursement, and in 
France, the patients would be more willing to pay for an insurance company or a hospital 
in order to access the solution. In any case, the research data and clinical evidence is 
required for supporting the solution and receiving the reimbursement.  
“But of course, this requires then that we have evidence to support the value of the system 
so that we can show that the pain is decreasing, the patients are more functional, they 
are maybe able to be less out of work or increase their work productivity or so. So, 
that you can show something concrete and then there’s willingness for the society to 
kind of compensate, reimburse, for that. If we think that this is feasible, this is the 
route we can take” —Respondent 8, Finland 
The respondents were requested to either choose a high price with low number of 
customers or a low price with high number of customers. The division of responds are 
depicted in Figure 24. Five of the respondents were implicit about offering the solution 
with low price for reaching a high number of customers. The use of such pricing allows 
the client company to have variety on the feedback and further gain an understanding 
about the customers’ behaviour in the platform. Furthermore, low price would aid the 
high acceptance among the patients and support the aim of reaching a standard therapy 
with the solution. In contrast, high price would create a niche product and the competitors 
would simply do the same, but with a much lower price. Moreover, it was considered that 
the patient would not necessarily choose the digital solution, that has the same high price 
as the physiotherapist. There are numerous low back pain patients all over the world that 
can be reached with a low price. One of the respondents agreed on reaching high number 
of customers with a low price but concluded that the client company’s core competencies 
cannot be utilized in that case.  
“But in a way, if it wasn’t [client company], I would maybe answer that probably the 
second because reaching […] there's lots of pain patients with reasonable pain, you 
could reach lots of patients. That […] sound[s] very attractive but then it's, like said 
that, it's not utilizing at all what we know and our kind of people and the organizations 
in the countries which we have available.” —Respondent 8, Finland 
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In the US markets, the option of low price was considered as more attractive whereas in 
a smaller market the high price might be forces because the market penetration is more 
difficult. The digital solution would most probably be distributed through health care 
organizations where the volume might not be as high and, consequently, the price needs 
to be increased.  
Two of the respondents did not choose either the low price or a high price, but rather gave 
the conditions under which either option would be viable. If the product is highly unique 
and difficult for competitors to copy or it is distributed by the hospitals, then the high 
price option was perceived as the more attractive one. However, if the solution can be 
copied easily or it is available at patients’ homes, then a low price was considered as the 
more viable one. Even though the price was considered to be higher in the beginning due 
to a lower customer base, the price still needs to be reachable for the customers. 
Furthermore, one of the respondents perceived a medium price and reasonable number of 
customers as the best option, rather than offering the solution for a low price. Only one 
of the respondents was implicit about offering a high price for receiving the correct 
customers.  
“— to be sure that at the beginning with the most appropriate price probably higher than 
expected you will send to the good people who are ready to pay your insurance. I 
mean, the stakeholders are ready to pay for what you will propose. Don't put a cheap 
price right from the beginning because if you don't have the customers, I mean enough 
customers right at launch, then you're dead.” —Respondent 5, France 
Figure 24 Low Price versus High Price 
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The Figure 25 depicts the division of respondents’ perceptions about providing only one 
pricing option against offering many pricing options. Half of the respondents preferred 
the option of many prices for different needs and customer segments. Firstly, the 
requirements of different countries were considered as a rationale for that. Secondly, 
various customers were considered to be using the solution for differing periods of time 
as well as have different preferences in regards of added features and used modules. 
Moreover, these several pricing options were perceived as an incentive for the patient. 
However, two of the respondents considered that only one price option is adequate 
because people would notice that the same product is offered for different prices.   
The factors that were perceived as affecting the price by the respondents are illustrated in 
Figure 26. The majority of the respondents considered that different features as well as 
the willingness to pay and attractiveness of the product influence the price the greatest. 
The features were considered as affecting the price increasingly, i.e. the customers are 
required to pay a higher price for different features and modules.  
 “you have like the, let's say, the basic model, that's that pricing and you get that kind of 
elements. And then the more you go […] higher the more elements you get, the more 
you pay. It's very much from the gaming world. Or you want to purchase one element 
more, you have to pay more. I mean, you want to get […] a new element, you have to 
pay more for it.” —Respondent 7, Finland 
“— there can be different levels […] there can be the basic level, but then also more 
advanced level and […] with a slightly higher price. So it's really hard to say at this 
point, but I think that it depends about the features, if there is a lot of […] interactive 
tools, like you can talk with the medical professional or you can contact us 24/7 easily 
access —of course, that needs to be easy access anyway. But still more, like, some 
additional services” —Respondent 1, Finland 
Figure 25 One Price versus Many Prices 
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The progress and customer’s accomplishments within the software were perceived as a 
decreasing factor affecting the price. After the customer has accomplished certain steps 
in the platform, he should be awarded, for example, by granting an access to additional 
features.  
“— for example, if you accomplished some level, do you get like a free month, for 
example. There has to be like these triggers built within the software, in my opinion.” 
—Respondent 7, Finland 
Many of the respondents considered the customers’ willingness to pay as an important 
factor that affects the price. The price ranges that the customers find attractive and 
reasonable, could be investigated through further research of customer perceptions. 
However, the added value and the overall attractiveness of the solution were perceived as 
closely related values of this factor.   
“I guess the added value has the most important influence on the price, maybe the 
attractiveness of your device as well as of […] the software will affect the price” —
Respondent 4, Germany 
The clinical evidence supporting the digital solution was perceived as an important factor 
that is also highly linked to the attractiveness of the product. Other factors raised by the 
respondents were time and the person accessing the solution.  
Figure 26 Factors Affecting Price 
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“— you cannot accept a high price, I would say. It depends on the added value; you have 
to show that there is an added value. That depends on your study of course. If you 
compare, for example, treatment of patients with or without such a digital solution, 
which use as an add on, for example, to their medical therapy and you can show, okay 
[…] have here much better results. You have then proven your concept and you can 
present […] that people are benefit from such a digital solution. […] that will have an 
influence on your price, but I do not know what is the price level at all.” —Respondent 
4, Germany 
The VR headset is a prerequisite for being able to access the digital solution and the 
respondents’ perceptions about the possible option for acquiring the VR headset by the 
customer are presented in Figure 27. There was no unanimous or unambiguous opinion 
among the respondents, and they considered several differing and viable options for the 
VR headset delivery.  
The majority of the respondents agreed that the VR headset should be available for renting 
or loaning in the hospitals, clinics, or rehabilitation centres. A unanimous perception was 
that the VR headset could be rented for the patient’s treatment period and after that, 
returned to the health care centre. However, a concern of VR headset’s durability was 
raised by the respondents.  
“— if something that to do with rehabilitation or whatever, if they have to go to a clinic 
to do, then sometimes, […] you can share the handsets, aren't you? […] So, I think 
for the DTx for pain, then definitely from the customer’s perspective they should be 
acquiring one of those.” —Respondent 3, The UK 
Figure 27 Options for VR Headset Acquisition 
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“But then also in hospital settings, we need to think […] if there is the VR headset, how 
many users we allow to one VR headset. And […] then it can be controlled with this 
application on phone or something. But then they could use the same VR headset 
there, so that not everyone would need to purchase a VR headset, that would be 
probably the preferred option for hospitals, so that not everyone would have their 
own.” —Respondent 1, Finland 
“Of course, the easiest would be that you get the VR glass, for example, you get like a 
trial out for 30 days, you get from the doctor, the VR glasses. That's one way of 
looking at this. And that's the easiest way.” —Respondent 7, Finland 
Half of the respondents perceived that, while the VR headsets’ prices are decreasing, each 
patient could acquire his own VR headset. However, the acquisition point and type varied 
between the respondents. On the one hand, if there are only few VR headset providers 
which products are compatible with the solution, the client company limits itself to those 
manufacturers and it can cause bottlenecks. On the other hand, if any VR headset can be 
used, the client company can be exposed to risks regarding non-tested hardware. One of 
the respondents proposed a list of compatible VR headsets that have been tested by the 
client company.  
“— do we need to define the VR headsets that are compatible with the software solution. 
So, do we need to show, […] make the validation and testing with these VR headsets 
that we are offering. So, if we have two or three different kinds of models of headsets” 
—Respondent 1, Finland 
Partnering with a VR headset provider and outsourcing the manufacturing activities was 
perceived as a viable option by the respondents. In this case, the customer would either 
order the VR headset from the partner company’s website or they are delivered directly 
to patient’s home after the purchase in the client company’s website.  
 “I mean, I think partnering, because I'm not sure that [client company] would want to get 
into the headset business. You know, as far as creating them.” —Respondent 6, USA 
“— do we plan to have the agreement with the VR headset provider so that […] they, for 
example, let us know if there is any changes in their VR headset, because these are 
also evolving, […] and does this have an effect to the software use. […] I think it 
should be as part of the package so, that if you login and […] if you start this one 
where […] you log in, you purchase this one, then you would be able to get the VR 
headset also through that link.” —Respondent 1, Finland 
6.2.6 Product Cost Structure 
The factors affecting the product’s cost structure perceived by the respondents are 
presented in Figure 28. The majority of the respondents recognized the costs related to 
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the development and continuous improvement of the software as one of these factors. The 
respondents mentioned, for example, the initial building-up phase of the library of the 
activities, maintenance of the software, and adding features according to the customer 
feedback, as development related activities.  
“Well, once you launch this kind of software, it's already old. So, you need folks […] who 
are developing this on daily basis. So, […] you come out with a version […] 1.0, but 
you have to have […] the next version ready in a couple of months, basically. So, you 
need folks who are all the time looking new elements to develop the software. And 
then also, in order to be really user friendly, you need constant feedback from the 
patients and the doctors what they're telling about the software. So, you need people 
who are also discussing […] the customer aspect, the account managers who are 
talking […] so what's the feedback we're getting— there’s many elements.” —
Respondent 7, Finland 
The costs related to sales and marketing, such as building the brand, raising awareness, 
and eventually delivering the solution for the customers, were perceived as cost factors 
by most of the respondents.  
“And then you need somebody in order to build the brand for this. You need somebody 
who's ready to allocate a certain amount of money for the branding and marketing and 
somebody who's willing to, in the future, build the brand for this.” —Respondent 7, 
Finland 
Each respondent mentioned, one way or another, the costs related to the hardware and the 
VR headsets. Not only were the costs related to the hardware itself (e.g. manufacturing, 
payments for the partner, etc.) mentioned but also the costs related to the support services 
that need to exist for technical problems.  
Figure 28 Factors Affecting the Product Cost Structure 
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“— when you're dealing with anything hardware, then you're dealing also with product 
defects, repairs, returns […] there's all sorts of organizational things need to go into 
place when dealing with hardware devices, that the company should be ready to deal 
with. So, almost like device companies have to deal with the stuff.” —Respondent 6, 
USA 
“But the problem with your solution is that you will have a VR tool on your device in 
patient hands. So, for example, if the headset fall on the ground and get broken and 
the patient should have access to someone and you need to change the headset or to 
find a solution to change the headset quite quickly, because if it takes you two weeks 
or three weeks to change the device to the patient, the patient will switch and will 
never come to […] your application again.” —Respondent 5, France 
Furthermore, the costs related to the maintenance services of both hardware and software 
were mentioned by the respondents.  
“— you should also take into account all the maintenance of your devices. So, who will 
pay for that? Who will do that? Do you have to move to the patient's home, or will 
you ask the patient to come back to the hospital or to […] somewhere […] to take 
care of the device.” —Respondent 5, France 
The evidence is needed to support the business case as well as to increase the 
attractiveness of the solution and accountability for the customers. Thus, almost half of 
the respondents identified the research and development related costs as evident.  
“But I would say that the biggest cost is the R&D project,” —Respondent 1, Finland 
In addition, one of the respondents mentioned the regulatory costs arising in the beginning 
whereas another respondent considered the costs of the partners having an influence on 
the price. Furthermore, two of the respondents recognized the economies of scope as a 
benefit and believed in adding new features, indications, and activities to the same 
platform in the future.  
“So, it's not just—It could also become a vehicle of secondary product to push the other 
[client company’s] businesses.” —Respondent 3, The UK 
6.2.7 Challenges 
The challenges regarding the digital solution perceived by the respondents are illustrated 
in Figure 29. Almost each of the respondent recognized the challenge of adopting the 
solution by some of the population groups as well as the prejudices that these groups 
might possess. Furthermore, the challenge of committing and engaging people into the 
platform was also perceived by many of the respondents. However, majority of the 
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respondents concluded that training and building awareness for the purpose of developing 
an understating about the platform’s functionality, is crucial.  
“— then is to do with convincing people […] study data to show the efficacy. Because 
again […] it's not traditional medicine, there will be people who can be quite sceptical. 
And thinking some of these things could just be placebo effect and playing with the 
mindsets and things like that. So, […] I think to communicate the real benefit with 
evidence could be potentially challenging.” —Respondent 3, The UK 
“So those are the areas that I would really concentrate on in the final execution of a project 
like this, because that's where I think most of the trouble will happen. In the adoption 
of this type of technique.” —Respondent 6, USA 
 “I think the challenge could be the belonging of the patient to your solution. If it's too 
complex or if it's not enough customer-oriented then […] they [patients] will never 
adhere to the solution.” —Respondent 5, France  
It was perceived as vital that the medical community is acknowledged by the solution and 
the clinical evidence exists to support the solution for the professionals to accept the 
solution. Moreover, if a person is not tech-savvy, there can be increased concerns to use 
the solution as well as lack of knowledge in accessibility related issues (e.g. acquisition 
points). Many of the respondents considered the older population as such a population 
group.  
“— there is maybe some kind of differences in acceptance of the digital technology. Like 
there is for anything related to digital […] especially the older generation, consider it 
to […] little bit strange to be doing something that they have used to.  […] [such as] 
wearing maybe virtual classes: “what is this?”.” —Respondent 8, Finland 
One of the respondents mentioned that even the medical professionals might be concerned 
about a digital solution taking their jobs and due to that be reluctant towards the device. 
Figure 29 Challenges 
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Furthermore, the image of pharmaceutical company providing a digital solution could 
affect certain patients’ adoption of the solution. However, some of the respondents 
perceived the challenges regarding adoption of the solution as merely a barrier. Therefore, 
the patients who have already tried several treatments, would be willing to try another 
one.  
“So, you have to have really high motive to seek this kind of a treatment. […] in my 
opinion, the patient has already gone through different kinds of steps. The person has 
tried different kinds of measures to fix […] his or her problem.”—Respondent 7, 
Finland 
“— if you have severe enough pain and there is no relief, and I think the […] willingness 
to try anything […] increases. So that maybe this is not then […] obstacle in the end, 
but it might be, […] that there is [sic] different levels of acceptance, I could think.” 
—Respondent 8, Finland 
One of the respondents considered the new type of marketing, high competition, and 
various selection of products available as challenges in the digital economy.  
“— what is crucially important […] is also the branding so how do you brand this, how 
do you become […] the brand […] in the world, which is just noise of different kinds 
of products, how do you become the signal that ‘You should get this one.’? That's the 
element.” —Respondent 7, Finland 
Availability issues and accessibility options for the customers were considered as 
challenges by some of the respondents. Furthermore, the challenge was linked to 
discovering the correct channel for delivering the solution as well as deciding on the 
appropriate price. In fact, the cost-related challenges, not only from the customer’s point 
of view but also from the company’s point of view, were mentioned by more than a half 
of the respondents.  
“And if this equipment is not purchased by the single patients and that it's only in the 
clinics, then it's of course a question of how much that equipment would cost and 
whether it would be a business or not. Because if only [the] clinics would buy these 
equipments [sic], and the cost would be low, it will not be the big business enough 
for us to, let's say, fully capitalized this project,” —Respondent 2, Finland 
Many of the respondents were concerned about finding a payer for the solution and the 
possibilities of reimbursement. Moreover, the regulatory and legal aspects were 
considered as challenges arising from such a digital solution.  
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“If you want to have a medical tool that will be reimbursed on in Finland or another 
European country, then the important stakeholders will be the payers. And you will 
need after that stakeholder who will convince the payers to take into your solution 
and propose it on a national basis for improving the management of the disease.” —
Respondent 5, France 
“I would say that the regulatory environment in each of these countries, like how these 
kind of VR tools […] how these are regulatory related and, what kind of criteria does 
these need to fulfil in these countries so taking these into account in the development 
phase can also help to remove the barriers.” —Respondent 1, Finland 
“— then I'm not familiar what type of IPR we have here. So how we can protect our 
position, because if we are selling this […] and it would become some kind of 
treatment then it's quite soon I would guess that the Chinese company or some other 
would come with a similar type of equipment but with the simpler solution - cheaper 
solution and simpler.” —Respondent 2, Finland 
Few respondents also raised the challenges that can be related to the hardware and their 
potential technical problems. Other challenges mentioned by the respondents concerned 
the loss or limited human interaction, as well as the lack of knowledge of the digital 
solutions by the client company at the moment.  
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7 ANALYSIS 
The results arisen from multiple-case study are analysed through a comparison of the case 
companies’ business models. Furthermore, the analysis of results from in-depth 
interviews presents the important characteristics of the business models perceived by the 
stakeholders. Finally, the analysed results are summarized in the form of developed 
business model suggestion for the client company.  
7.1 Comparison of Case Companies 
When comparing the five case companies’ business model approaches, similarities can 
be identified even though the solutions, used devices and technologies differ between the 
companies. However, each case company is in the digital therapeutics line of business 
which could indicate that the business model approaches show similarities when 
compared with each other. For the companies to receive a clearance from the regulatory 
bodies, clinical trials need to be conducted in order to provide evidence to support their 
therapies and solutions. Each of the case company is performing clinical research for the 
purpose of receiving a clearance from regulatory agencies, supporting their solution’s 
development, or supporting the accountability of the solution for the customers. The 
global markets can be reached through registering the solution as a medical device, 
receiving CE mark from the EU, and achieving FDA clearance. All these require clinical 
trials evidence to support the solution’s functionality. 
7.1.1 Value Proposition 
The comparison between the case companies’ value propositions is presented in 
Appendix 9. The value proposition of each case company contains the promise of cost 
reductions for the customer groups. Whereas the cost reductions for medical professionals 
and patients remain in fewer face-to-face meetings, the employees benefit from less 
absenteeism owing to the treatment. Furthermore, non-medical treatments, preventive 
care, external control, and home-based exercises allow the hospitals, pharmaceutical 
companies and patients benefit from the decreased costs. The analysis of generated data 
for the purpose of following the patient’s progress is one of the target functions in each 
company’s business model approach. 
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Almost each of the case company recognizes the gamification as a factor that engages the 
patients into the treatment. Kaia health emphasizes the importance of combining the 
mental and physical health whereas SilverCloud Health and Happify’s solutions focus on 
treating mental health issues. All these three companies offer support, mentoring, and 
encouragement from either an assigned person, medical professional, or a community of 
other members. Gamification or motivating patients through coaching and mentoring 
encourage the patients to continue the treatment and can even intensify the treatment 
compared to traditional therapeutics. Furthermore, SilverCloud Health and Happify 
promote the non-existing entry barriers related to accessibility and stigma that might be 
associated to mental health issues. The hospital-based company MindMaze is the only 
case company that cannot provide the benefit of convenience and easy accessibility of the 
solution that can be used at home and with patient’s own time. Furthermore, Kaia Health, 
Happify and SilverCloud Health offer educational material about the treated conditions 
which allows the patient to gain understanding about their state of health. 
A clear difference can be noticed in the focus of different customer segments that the 
products are mainly targeted to. Kaia Health and Happify’s products are most 
distinguishably divided between consumers and businesses, while MindMaze’s devices 
and SilverCloud Health’s solutions are targeted to rehabilitation centres, clinics, and 
hospitals. In contrast, XRHealth has not drawn a clear line between the business and 
individual consumer sales. Furthermore, Kaia Health, SilverCloud Health and Happify 
are all targeting the employees of private companies and their employees and the 
customers of insurance companies as the end-users of the solution. In addition, XRHealth 
and Happify are both considering pharmaceutical companies as their target groups 
because the solution provides efficiency and assistance for clinical trials. One of the 
SilverCloud Health’s customer segments is the universities that offer the solution for the 
students.  
The differentiation between the case companies can be recognized in their 
complementary value propositions. For instance, Kaia Health highlights the non-medical 
treatment of back pain and provides the Kaia Motion Coach as a digital personal trainer. 
In comparison, XRHealth promises patient satisfaction, and External Control platform is 
offered for medical professionals to monitor the treatment and patients’ progress. 
Furthermore, MindMaze ensures the continuum of care from the early involvement 
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whereas SilverCloud Health offers scalable solutions for each customer group. Finally, 
Happify concentrates on providing easy accessibility for each individual by, for example, 
considering the cultural differences and physical limitations.  
The case companies’ value propositions contain the aspect of personalization and 
engaging the patients to the treatment. Happify and Kaia Health use initial questions, i.e. 
questions about the patient’s condition when the service is initially entered, and data 
analytics to personalize the treatment according to the patient’s level and progress. On 
the contrary, SilverCloud Health relies on the supporter’s vision and assessment with the 
personalization. In addition, XRHealth and MindMaze’s solutions rely on the medical 
professional’s assessment of the level of personalization. All other case companies, 
except Kaia Health, allow the customer to choose the preferred game, module, or activity.  
7.1.2 Interface 
The comparison of interface characteristics of each case company is presented in 
Appendix 10. Each case company contributes to providing a user friendly and easy to use 
platform. All other companies, except MindMaze, offer the opportunity for contact with 
a real-life person, such as a supporter, mentor, or a community of other subscribed 
members. Kaia Health and XRHealth trust in self-service of the patients and MindMaze, 
SilverCloud Health and Happify offer a customer support and contact information for the 
delivery of the solution. Social media is used by Kaia Health, SilverCloud Health and 
Happify to interact with the customers. However, some of the interaction possibilities 
differ between the companies. Whereas SilverCloud Health offers interactive exercises, 
the analytical tools by MindMaze offer a different kind of approach for the interaction. 
XRHealth offers customers’ own sites in their websites and Kaia Health ensures to answer 
the reviews in the application stores. Moreover, Kaia Health offers B2B customers 
maintenance services and a Kaia Campaign to promote the solution for the end-users.  
Each case company has considered the aesthetics of the interface. Furthermore, Kaia 
Health provides clear, factual, and stepwise guides for setting up the solution. In each 
company, the variety of games and activities makes the customization of the content 
possible. MindMaze offers user-calibrated activities whereas XRHealth’s Data Portal can 
be customized according to the customer’s needs. SilverCloud Health offers a possibility 
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for companies to have the solution customized based on their needs, and the care can be 
chosen to be self-directed or coached.  
7.1.3 Service Platform 
The characteristics of service platform and their comparison in each case company is 
illustrated in Appendix 10. The case companies’ architectural solutions vary between 
each other and have both similarities and differences. XRHealth, SilverCloud Health and 
Happify have an open API whereas Kaia Health and MindMaze trust in a closed propriety 
software. Furthermore, XRHealth has opened the platform for third-party developers that 
can develop additional games and activities into the platform. XRHealth, and SilverCloud 
Health’ web-based portals can be easily integrated to customers’ own devices. 
Nevertheless, XRHealth’s platform can only be accessed with a VR headset. All the 
companies’ solutions support different operating systems and, excluding MindMaze, the 
platforms can be used with patient’s own device.  
Each of the case company offers the solution in their own websites for purchasing. Kaia 
Health and Happify offer the solution in application stores for individual consumers to 
download, whereas XRHealth and MindMaze need to be contacted and sales 
representatives will offer the solution for the potential customers. Furthermore, 
XRHealth, MindMaze and SilverCloud Health provide the solutions for acquisition 
through their partners. Kaia Health’s solution can be accessed for free through a trial 
period, after which the content can be accessed only after a subscription. In comparison, 
Happify’s solution have a free access, but only to limited features, and the entire solution 
can be accessed by subscribing. XRHealth and MindMaze can only be accessed through 
subscription and SilverCloud Health’s solution is only available through the partners such 
as insurance companies, hospitals, universities, or other private companies. Moreover, 
Kaia Health offers access to its customers through certain private insurance companies’ 
reimbursement plans in Germany. In addition, Happify has considered the barriers for 
accessibility and offers the solution in eight different languages as well as for visually 
impaired individuals.  
7.1.4 Organizing Model 
The comparison of case companies’ organizing model is presented in Appendix 11. Each 
case company’ core business process includes the problem-solving through results from 
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clinical trials and gathered health data by the platform. Additionally, all must manage the 
platform and network with partners. The importance of partnerships can be noticed from 
each business model where the partners are an essential link in delivering the solution for 
the end-users, developing the treatments through clinical trials as well as providing 
funding. Clinics, hospitals, health care professionals and rehabilitation centres are 
essential partners for each case company. As medical device companies, Kaia Health, 
MindMaze, and SilverCloud Health have partnered with private companies that offer the 
solution for their employees. Furthermore, all the companies, except MindMaze, offer the 
solution for subscribers of private insurance companies that they have partnership with. 
For the purpose of using the solution in clinical trials, Kaia Health, SilverCloud Health 
and Happify have partnered with pharmaceutical companies. Some differentiation can be 
noticed in case companies’ partnerships as well. XRHealth offers an opportunity for third 
parties to develop additional applications to the platform through partnership. 
Furthermore, XRHealth has a partnership with VR headset manufacturing company 
Oculus which headsets are the only ones compatible with XRHealth’s solution. Finally, 
SilverCloud Health’s partnership with universities allows the solution delivery for the 
students. 
The key resources required by each case company are the financial resources. 
Additionally, in a knowledge-based industry, where clinical evidence is required to 
support the medical claims, human resources are essential. However, as a device-based 
company, MindMaze requires physical resources as well, in case they are manufacturing 
the devices by themselves. In each case company, the partners contribute as offering the 
access to the end-users and eventually, deliver the solution for the patients. Kaia Health 
and Happify’s partners provide capabilities that the case companies are lacking. The third-
party developers deliver added value for XRHealth’s customers and consequently, to the 
company itself. Furthermore, the partnership with Oculus supports the ultimate access to 
XRHealth’s platform while Kaia Health has received financial resources from the 
partners.  
7.1.5 Revenue Model 
The comparison of case companies’ revenue models is illustrated in Appendix 11. As the 
main pricing strategy, each case company uses the subscription sales while the pricing 
mechanism is based on different factors. Kaia Health has different prices for B2C and 
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B2B customers. Kaia Health and Happify’s pricing for B2C customers is dependent on 
time committed to the solution whereas Kaia Health’s B2B customers pay per active user. 
MindMaze and SilverCloud Health pricing is based on one price that is paid in different 
time intervals – MindMaze monthly and SilverCloud Health yearly. Conversely, 
XRHealth offers different prices based on accessibility to features and modules of the 
platform. Furthermore, while XRHealth’s VR headset is acquired from the partner 
company, MindMaze sells the devices themselves.  
Each case company’s cost structure can be recognized as value-driven and their main 
costs include people and research and development related activities. Furthermore, Kaia 
Health and SilverCloud Health identify the costs generated from the maintenance. Each 
case company’s platform can be utilized for delivering additional features, activities, 
games, and treatments. Thus, the benefit from economies of scale exists for each case 
company.  
7.2 Stakeholder Perceptions 
The stakeholders perceived barriers and challenges in delivering the digital solution for 
the customers. The major challenge of adoption was linked to the novelty of the treatment 
that may cause prejudices in certain customer groups such as the elderly and not tech-
savvy people. Furthermore, the patients that have already tried everything are the ones 
acquiring the digital solution, if the price is affordable for them. The challenge of 
reimbursement as well as the legal and regulatory aspects can slow the process of market 
penetration whereas the availability and accessibility issues are potential concerns. In 
conclusion, there are many barriers that the client company needs to overcome before the 
digital solution can be delivered to the customers.   
7.2.1 Value Proposition  
The increased interest towards self-management enhances the digital solution’s 
attractiveness. The interviews established that the digital solution brings added value for 
the customer in terms of treating low back pain. The non-medical aspect of the solution 
and lack of side effects can increase the patients’ quality of life. Moreover, the 
gamification of the treatment enhances the patients’ motivation and commitment to the 
treatment through the factor of engagement. This engagement can further be intensified 
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by making the patients feel acknowledged and encouraged. Monitoring the patient’s 
progress is one of the perceived value propositions that would be beneficial for both the 
patient and the medical professionals. The gathered health data is also attractive for the 
client company to receive results from the treatment. Furthermore, the novelty of the 
digital solution’s treatment generates an interest to new experiences among patients 
whereas the cost-effectiveness attracts different organizations. The likelihood for 
acceptance could be high among certain population groups, i.e. younger generation, when 
the price is acceptable and enough clinical evidence supports the effectiveness.  
The acceptance among patients can further be increased by receiving the acceptance from 
the medical professionals that recommend the treatment for the patients. Thus, the 
medical professionals and different organizations (e.g. hospitals, patient organizations, 
insurance companies, etc.) should be targeted on first, even though the individual 
consumers are a feasible target group too. The individual consumers reaching for the 
treatment provided by the digital solution can be used for data collection purposes and 
proving the feasibility. However, the credible brand and awareness building are essential 
for reaching a wide audience. The organizations are a vital connection between the digital 
solution and the end-user because these organizations deliver the solution for the patients, 
educate them about its functionality, and monitor the results. Hospitals and medical 
professionals are the most important stakeholders with their expertise in treating the 
patients and thus, having the credibility for recommending the digital therapeutics 
solution’s treatment. Additionally, they support in awareness building among patients 
seeking for help. The patient organizations and pain clinics can provide the digital 
solution as an additional or alternative treatment of managing pain. Especially in 
Germany and the USA, the private insurance companies are important stakeholders for 
offering the digital solution in their health insurance packages. Furthermore, the private 
companies as a stakeholder can provide the solution for the employees through corporate 
welfare packages. 
One of the complementary factors of the digital solution is the accessibility. The digital 
solution can be used at home by offering a different type of accessibility. Moreover, the 
digital solution provides a different approach for treating pain that does not expose the 
patient to the stigma related to mental health issues. The add-on therapy lowers the 
patients’ perceived barriers for seeking help. The personalization of the treatment for the 
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purpose of meeting the patients’ needs is essential owing to different levels, limitations, 
and expectations towards the treatment. When the personalized content is addressed to an 
individual patient, the engagement, attractiveness, and commitment are increased. 
Moreover, the possibility for choosing between various activities or creating an element 
of surprise through differing scenarios, motivates the patient to return the digital solution 
every day. The gathered health data can be used for the purpose of personalizing the 
treatment through a combination of AI, patient, and medical professionals’ assessment. 
The AI’s follow-up on the progress and reminders about the patient’s activity level is an 
effective way to analyse the data. However, the medical professionals are needed for 
setting the parameters, monitoring the risk, and encouraging the patient for movement. 
Furthermore, the patient should choose the level of intensity or activity according to the 
condition.  
7.2.2 Interface 
The clear and guided setup process support the interface’s user-friendliness that is a vital 
aspect of the entire digital solution and a prerequisite for acceptance and adoption by the 
customers. Moreover, customers perception of a user-friendly interface should be 
continuously improved based on the feedback received. The outlook, design and the 
aesthetics need to be considered for enhancing the customers’ interest towards the 
solution by making it attractive and encouraging them to use the interface. There needs 
to be a possibility to customize the content according to the patient’s own interest for 
committing different types of people into the solution. Furthermore, the customization 
should not only be limited to changing the colour of the background or setting the scene, 
but also considering the limitations of patients.  
The collection of data in the interface is one of the interaction possibilities that allows the 
monitoring of patient’s progress. Furthermore, the saved data acts as a valuable source 
for medical professionals in face-to-face interactions. In fact, the interaction with medical 
professional is essential for the patient to share their progress and request help. The 
interaction with communities of patients with similar condition should be made available 
for further support from others. Furthermore, the motivation for achieving certain goals 
is enhanced when the accomplishments can be shared in social media. Reminders, 
purchasable add-ons, and questions about the patient’s state tie the patient into the 
interface emotionally. The haptic motors in the handset ensures the correct movement.  
J. Vilponen: Digital Therapeutics Solution and Business Model Creation 
107 
 
7.2.3 Service Platform 
The service platform is a proprietary and closed software while having an opportunity for 
collaborating with third-party developers that provide additional features, activities, or 
personalized solutions. The service platform should be supported by different operating 
systems for larger customer adoption. One of the options for delivery channel of the 
digital solution are hospitals, clinics, and medical professionals in order to guarantee a 
safe service delivery. However, several options for different target groups as delivery 
channels should be available. For individual patients, the solution should be available for 
download, for example in an application store, or client company’s website with a code 
provided by a medical professional. Through a trial period, the customer would be able 
to preview the solution before the purchase decision of either additional features or access 
to the solution itself. The limited free access would enhance the adoption and further 
success of the digital solution.  
7.2.4 Organizing Model 
The core business processes include sales and marketing in order to deliver and making 
the solution available for the customers as well as promoting it to reach wider customer 
base. Research and development activities are essential business processes for creating 
the clinical evidence base for the digital solution. The support from the clinical trials 
further enhances the probability of recommendation by the medical professionals. The 
platform management related processes, such as a support function and maintenance 
services, are required in case of technical problems with either the software or hardware. 
Furthermore, a core business process is the continuous improvement of the solution for 
acquiring the commitment of the patients and credibility as a company.  
The partnership with a software, IT consultancy, or DTx company is essential for offering 
technical expertise in developing and maintaining the digital solution. Furthermore, these 
companies are vital for acquiring customer base and building networks. Hospitals, clinics, 
and medical networks can provide support in clinical trials whereas the patient 
organizations assist in building awareness among potential customer groups. Partnerships 
with advisory boards offer networks for gathering insights, knowledge and acquiring a 
thorough understanding about the needs regarding the digital solution’s delivery. In 
addition, insurance company partnerships allow the availability of the digital solution for 
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the subscribers of health insurances. The key resources of acquired from the partners are 
related to technology, digital content, and digital marketing. Client company’s key 
resources include the sales and marketing as well as research and development in regards 
of conducting clinical trials. Furthermore, the existing personnel’s knowledge and 
expertise are exceptional resources.   
7.2.5 Revenue Model 
The revenue model of the digital solution should be based on a subscription fee because 
it engages and commits the customer into the product. However, the unsubscribing from 
the platform is made effortless when the customer does not use the solution anymore in 
order to avoid any poor reviews. The subscription fee based on modules and features is 
one of the feasible options for pricing the solution. The additional features, various 
modules, and other services could then be priced differently. Especially, for B2B 
customers the volume or license-based pricing would succeed due to the promise of 
certain number of customers. However, a payment per active user would be more 
attractive option from the customer’s point of view. The reimbursement of the digital 
solution is a viable option in certain parts of the world, but requires extensive research, 
expertise, and clinical evidence which could postpone the market access.  
A low price allows the high reach of the customers which results in acquiring a larger 
variety of customer perceptions about the platform. Furthermore, it would support the 
acceptance by the individual consumers and create a standard therapy for treating back 
pain. In contrast, high price would create a niche product that needs to be unique enough 
to prevent copies from the competitors. However, in the beginning the high price is 
inevitable due to a low customer base. Thus, the low-price suits for individual consumer 
target group whereas the high price is more suitable for target group of the organizations. 
Nevertheless, many price options and alternative methods are needed for different target 
groups and differing needs.  
The features of the digital platform affect the pricing increasingly which supports the 
module-based pricing mechanism. The pricing can also be linked to time, treatment 
period, or the person. Moreover, the patients accomplished progress needs to be 
acknowledged by, for example, granting an access to additional features. The digital 
solution as well as the price range need to be attractive enough for patients in order to 
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enhance the willingness to pay. Furthermore, the attractiveness can be increased through 
clinical evidence supporting the product. The VR headsets should be made available for 
rent or loan in the health care centres and a partnership with a VR headset company could 
support this acquisition for the organizations. However, it would be feasible, especially 
for individual consumers, to make the platform compatible with several VR headsets to 
avoid limitations of one manufacturer. In this case, a list of compatible VR headsets 
should be made available for patients that are willing to acquire their own headset.  
Eventually, the digital solution has a value-driven cost structure that emphasizes the 
importance of continuous development according to the user feedback. Thus, the 
development related activities, such as software maintenance, improving features, and 
mapping user requirements are costs arising from supporting the digital solution. 
Furthermore, the sales and marketing costs are relevant as building brand, raising 
awareness, and providing the solution for the customer are essential for value delivery. 
The costs related to the VR headset and hardware consist of partner payments, support 
services and maintenance. The most evident costs are related to research and development 
activities which are required for supporting the clinical evidence of the digital solution. 
However, the digital solution allows the additional features for the same platform and, 
thus, receiving benefit from economies of scope.  
7.3 Business Model 
Based on the comparison of case companies and identification of similarities between 
them as well as the stakeholder perceptions, a suggestion for a business model has been 
developed using the VISOR framework. The VISOR business model for client company 
is presented in Appendix 12.  
The value proposition of the client company includes a new, non-medical treatment that 
lacks side effects. Non-medical and digitalized treatment results in cost reductions for 
both the hospitals and the patients. The gamification of exercises fosters the engagement 
of patients in completing the activities and, also, returning to them. The pain can restrict 
the patients’ movement considerably and thus, gamified exercises expose the patient into 
movement almost accidently. The solution includes a mentor that encourages the patient 
during the physical exercises. The value proposition of mentoring is one of the essential 
ones and the importance of a multimodal therapy in the treatment of chronic low back 
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pain is emphasized. A monitoring tool for following the progress creates additional value 
for both the patient and the medical professional.  
The client company’s customer segments are individuals that suffer from chronic low 
back pain whereas the digital solution’s focus is on the treatment of chronic low back 
pain. However, the main focus customer segment is the organizations that need to be 
convinced before targeting individual consumers. One of the customer segments is the 
medical professionals that recommend and, ultimately, deliver the solution for the 
patients. The clinics and hospitals can be considered as customers because the solution is 
offered through them. Furthermore, the patient organizations, private insurance 
companies, and employees are target groups that can build awareness among the potential 
customers.  
The differentiating factors of the client company’s solution include the easy accessibility 
that provides convenience for the patient as the solution can be used at home. The non-
existence of stigma and other entry barriers enhances the customers’ accessibility for the 
solution. Furthermore, to increase the effectiveness the digital solution can be used as an 
additional therapy for the more conventional type of treatment that includes, for example, 
face-to-face meetings with a medical professional and medication. The value proposition 
of the client company contains personalization of treatment. This is done by data analytics 
to monitor the patient’s progress and altering the treatment according to the patient’s 
needs and level. A medical assessment of the health data is also included in the digital 
solution and the patient is able to choose different modules and features.  
The setup process can be done as a self-service with the help of clear instructions and 
guides whereas the user-friendliness is considered by developing an interface that is easy 
to use. The interaction possibility with a mentor or supporter is provided as well as the 
interaction with a community with other members. Additionally, the customers are able 
to receive help when problems occur through support services. Social media platforms 
are utilized in interacting with the existing and potential customers as well as reacting to 
reviews and development ideas. The solution’s websites will have customer’s own pages 
which includes account details such as gathered and analysed data. The aesthetics, design 
and outlook of the interface are considered for increasing the attractiveness of the 
software. In addition, the patient will be able to personalize the initial screen’s 
environment by choosing a place that they find the most calming. Other possibilities for 
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customization, such as colours and backgrounds are offered. The patient’s limitations are 
also considered through possibilities of customization.  
The service platform is a closed proprietary software due to legal and regulatory aspects. 
The client company needs to manage the content in the software in order to be accountable 
and credible. The platform supports various operating systems to offer the solution for a 
wider audience. The channel for creating awareness about the solution is the client 
company’s website which will have access to solution’s own pages. The website will act 
as the distribution channel of the solution too by including client company’s sales 
representatives’ contact information there. In addition, the awareness is created through 
partnerships with other companies and healthcare professionals. These partners are the 
distribution channel of the solution as well. For the preview of the solution, a limited free 
access is granted through a trial period. After the trial period, the customer needs to 
subscribe to the solution in order to have a full access.  
Client company’s core business processes are sales and marketing as well as research 
and development activities. The clinical trials create important evidence and results about 
the solution’s effectiveness. An essential business process is the platform management, 
developing the platform and promoting it. Thus, the partnerships and networking are 
important for acquiring capabilities and knowledge. These activities contribute in 
environment scanning that results in improving the solution continuously. In addition, 
support and maintenance processes are required for both the software and hardware.   
The key partnership for the client company is with a software company that is developing 
the digital platform. The company is managing and maintaining the technical aspects of 
the platform. Nevertheless, the partnership with the VR headset provider will be essential 
because the solution cannot be utilized without them. In addition, the healthcare 
professionals, clinics, and hospitals form a partnership group that recommend and deliver 
the solution for the end-user. Patient organizations are for building awareness among the 
customers whereas the partnerships with DTx companies and advisory boards contribute 
in providing valuable knowledge and consultancy.  
The human resources, that deliver and develop the value proposition for the customer, are 
considered as the key resources. People’s expertise and capabilities are essential in 
creating not only medical devices but also digital platforms in general. Also, clinical trials 
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and researching require a substantial amount of specialised knowledge. For the client 
company, the existing intellectual resources are an advantage. The company already has 
an established customer base with hospitals, clinics and healthcare professionals which 
facilitates in creating partnerships with these institutions. In addition, the potential 
customers, that would benefit from this type of treatment, can be contacted, and identified 
from the existing databases.  
Revenue is created by collecting subscription fees for the use of the platform. Business 
customers can have the possibility to choose from differently priced packages that vary 
in included features. The VR headsets are acquired from the partner but there are two 
opportunities in delivering the product to the customer. First option is that the client 
company purchases the VR headsets from the partner and then further sells them to the 
customer using bundled pricing mechanism. The second option is to guide the customer 
into the VR headset manufacturing company to acquire the product directly from them. 
Furthermore, the healthcare professionals could have the opportunity to purchase the VR 
headset for the business and rent or lease them for their patients. Pricing mechanisms used 
for B2C customers is list pricing which means that predetermined prices are offered for 
the subscription of the solution. As in the Kaia Health’s case, the prices can be fixed for 
different subscription periods. For B2B customers, the prices are negotiated and are 
customer segment dependent for example differing according to the number of subscribed 
patients.  
Value-driven cost structure creates the potential for creating the best value for the 
customer and making the solution a personalized experience. People, R&D related 
activities, platform management and outsourced services establish the costs of the 
solution. Also, if the VR headsets are acquired by the client company, it creates costs. 
The platform, though, benefits from economies of scope because the same distribution 
channels can be utilized when new exercises and activities are developed.  
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8 DISCUSSION AND FINAL CONCLUSIONS 
The final chapter of this thesis draws conclusions by presenting key findings from the 
research in relation to the reviewed literature. Moreover, the ability to answer the research 
questions is examined. Lastly, the theoretical and practical implications are presented as 
well as the limitations and future research are discussed. 
8.1 Key Findings 
The current needs in health care include personalization, cost-effective treatment, and 
easy accessibility. According to the literature (e.g. Chircu et al., 2017; Kvedar et al., 2016; 
Snowdon et al., 2015; Sverdlov et al., 2018) and findings from the multiple-case study, 
the digital solutions can provide a solution for these needs. In addition, similar benefits 
were recognized in the client company’s solution by the stakeholders. Furthermore, the 
increasing necessity for value-based pricing and quality of care can be supported by a 
more transparent assessment and monitoring of treatments’ results through the gathered 
health data that can be accessed by both the patient and the medical professional. An easy-
to-use and user-friendly interface combined with a thorough training and education might 
lower the barrier for adoption, especially among non-tech-savvy people. Moreover, the 
research results from clinical trials that support the digital solution’s effectiveness lower 
the barrier of medical community’s acceptance. Medical professionals remain as essential 
actors in recommending, building awareness, and delivering the digital solution for the 
patients.  
In the USA, the out-of-the-pocket payments of health care and private insurances are 
more common which can result in higher acceptance by individual consumers than in the 
EU. In the EU, the public health care systems and highly regulated reimbursement 
schemes require more convincing of policymakers. However, cost reductions, 
effectiveness, and lower accessibility barriers, can attract private organizations and 
insurance companies to include the digital solution in their portfolio. The challenges 
regarding the legal, regulatory, pricing, and cost-related aspects were recognized by the 
stakeholders as well as supported by the literature (e.g. Afra et al., 2018; Chircu et al., 
2017; Coye et al., 2009; Hird et al., 2016; Lameire et al., 1999). The costs regarding the 
maintenance of hardware and software as well as developing a support function, create 
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additional costs and require company’s effort and time. The pricing mechanisms between 
the health care and digital content can create contradictions. Thus, novelty pricing and 
reimbursement schemes that combine a traditional business (i.e. health care and 
pharmaceutical industry) and arising businesses (e.g. digital therapeutics, digital health) 
need to be fully addressed in order to accomplish acceptance in a wider public scale.  
8.1.1 Research Questions 
The first research question (RQ1: What kind of business environment exists for the client 
company?) was answered through a literature review that considers the challenges, 
barriers, and needs that exist in the business environment. The existing health care and 
reimbursement systems as well as the pricing strategies of digital content provide the 
understanding of underlying design space for business model creation. The health care 
needs and digitalization opportunities in pharmaceutical industry, contribute to 
recognizing not only the benefits of the digital therapeutics solution and but also the 
existing competition. Moreover, the health care systems and regulatory demands 
presented support the potential markets of the client company and existing markets of the 
case companies.  
The second research question (RQ2: From the business model perspective, what type of 
characteristics arise in existing digital therapeutics companies?) was answered by a 
multiple-case study. The business model characteristics could be recognized properly and 
supported the research aim as providing essential information about the existing digital 
therapeutic solutions. The third research question (RQ3: Which of these characteristics 
are feasible in the client company’s business model?) was answered through an analysis 
of the multiple-case study results that were compared to identify similarities and 
differences. Then, this comparison was utilized in the final business model creation as a 
confirmation of already used solutions that were perceived as feasible by the stakeholders 
as well in the context of the client company’s solution.  
The final research question (RQ4: Which characteristics are perceived important by 
different stakeholder groups within and outside the client company?) was answered 
through in-depth interviews. The results were analysed, and perceived characteristics 
were further utilized in the final business model creation.  
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8.2 Conclusions 
The aim of this thesis was to find a feasible business model for the client company and 
contribute to the needs of business model in the digital therapeutics field. A suggestion 
for a business model was developed based on the research of existing business models in 
the field as well as stakeholder perceptions about the important aspects of a business 
model, whereas the challenge with a reimbursement model remains to be further studied. 
Nevertheless, the developed business model does not provide straightforward and specific 
solutions, but rather supports in decision-making processes when the feasibility between 
several options are considered. Thus, it can be concluded that there is no one single 
solution for every digital solution company and a feasible business model is dependent 
on various factors, such as the chosen technical solution, demographic location of the 
company, capabilities, and partnerships. However, the awareness needs to be built among 
the customers and create an attractive enough solution, because, eventually, everything 
comes to the customer, and their willingness to adopt, use, and pay. 
This thesis contributes to the literature by providing new insights and knowledge about 
the business model characteristics of digital therapeutics companies. Furthermore, the 
combination of health care systems and digital content approaches digitalization from a 
relatively new angle. The practical implication of this thesis includes an opportunity for 
companies to innovate their current business model based on their product and service 
portfolios. More specifically, this thesis provides insights about the characteristics of a 
business model based on VISOR framework perceived as important in the pharmaceutical 
industry regarding the digital therapeutics solutions.   
8.2.1 Limitations and Future Research 
This thesis has potential limitations. The limited access to case companies’ information 
has restricted a complete understanding about the business model characteristics. Due to 
this limitation, some of the case company information is biased to researcher’s own 
interpretation of data acquired from the internet. Furthermore, the sample might not 
contribute to generalized results, because they might be biased to client company’s 
organizational culture and respondent’s personal level of knowledge and interest towards 
digital solutions and technologies. Thus, the future research should contribute in finding 
the customer and end-user perceptions about the digital solution as well, in order to find 
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out a more comprehensive business model. More specifically, the research about 
acceptable price levels and feasible delivery channels from the customer perspective, 
should be investigated further. In addition, in-depth interviews in existing digital 
therapeutics companies could be conducted for gaining a detailed understanding about 
their business models and feasible characteristics. Moreover, a country or region-specific 
research about market access opportunities with regards to the underlying reimbursement 
and regulatory processes could contribute in understanding the requirements for receiving 
a broader acceptance in the public health care systems. For the researcher’s own interest, 
a future research could be conducted about the motivation for final business model 
choices and their feasibility in a real-life context.   
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